{ "disease": "esophageal-cancer", "label": "Esophageal cancer", "url": "https://usebiotransfer.org/disease/esophageal-cancer/", "built": "2026-09-12", "facts_hash": { "answers": "5f6a888194a4", "targets": "0d158cc74074" }, "sources": { "targets": "Open Targets Platform GraphQL API v4", "trials": "ClinicalTrials.gov API v2" }, "retrieved": { "targets": "2026-09-12", "trials": "2026-09-12" }, "query": { "endpoint": "https://clinicaltrials.gov/api/v2/studies", "shape": "query.cond=&query.intr=&pageSize=200", "active_statuses": [ "ACTIVE_NOT_RECRUITING", "ENROLLING_BY_INVITATION", "NOT_YET_RECRUITING", "RECRUITING" ], "dedup": "by NCT id across synonyms", "study_types": "interventional counted in headline; observational reported separately", "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search" }, "targets": [ { "symbol": "TP53", "ensembl": "ENSG00000141510", "n_drug_entries": 9, "n_distinct_drugs": 8, "drugs": { "ALRIZOMADLIN": "PHASE_2", "CENERSEN": "PHASE_2", "CONTUSUGENE LADENOVEC": "PHASE_3", "EPRENETAPOPT": "PHASE_3", "IDASANUTLIN": "PHASE_3", "NAVTEMADLIN": "PHASE_3", "SIREMADLIN": "PHASE_2", "TEPRASIRAN": "PHASE_3" }, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Advanced Clinical" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "ERBB2", "ensembl": "ENSG00000141736", "n_drug_entries": 48, "n_distinct_drugs": 45, "drugs": { "AC-480": "PHASE_2", "AEE-788": "PHASE_1_2", "AFATINIB": "APPROVAL", "AFATINIB DIMALEATE": "APPROVAL", "ALLITINIB": "PHASE_1", "ANVATABART OPADOTIN": "PHASE_2_3", "AV-412": "PHASE_1", "BMS-690514": "PHASE_2", "CANERTINIB": "PHASE_2", "CP-724714": "PHASE_2", "CUDC-101": "PHASE_1", "DACOMITINIB": "APPROVAL", "DISITAMAB VEDOTIN": "PHASE_3", "ERTUMAXOMAB": "PHASE_2", "GANCOTAMAB": "PHASE_2_3", "HEMAY-022": "PHASE_3", "JNJ-26483327": "PHASE_1", "KBP5209": "PHASE_1", "KN-026": "PHASE_3", "LAPATINIB": "APPROVAL", "LAPATINIB DITOSYLATE": "APPROVAL", "MARGETUXIMAB": "APPROVAL", "MASOPROCOL": "APPROVAL", "MM-111": "PHASE_2", "MUBRITINIB": "PHASE_1", "NERATINIB": "APPROVAL", "PERTUZUMAB": "APPROVAL", "POZIOTINIB": "PHASE_3", "PYROTINIB": "PHASE_3", "S-222611": "PHASE_1", "SAPITINIB": "PHASE_2", "TAK-285": "PHASE_1", "TARLOXOTINIB": "PHASE_2", "TESEVATINIB": "PHASE_3", "TRASTUZUMAB": "APPROVAL", "TRASTUZUMAB BOTIDOTIN": "PHASE_3", "TRASTUZUMAB DERUXTECAN": "APPROVAL", "TRASTUZUMAB DUOCARMAZINE": "APPROVAL", "TRASTUZUMAB EMTANSINE": "APPROVAL", "TUCATINIB": "APPROVAL", "TUXOBERTINIB": "PHASE_1_2", "VANDETANIB": "APPROVAL", "VARLITINIB": "PHASE_2_3", "ZANIDATAMAB": "APPROVAL", "ZENOCUTUZUMAB": "APPROVAL" }, "approved": [ "AFATINIB", "AFATINIB DIMALEATE", "DACOMITINIB", "LAPATINIB", "LAPATINIB DITOSYLATE", "MARGETUXIMAB", "MASOPROCOL", "NERATINIB", "PERTUZUMAB", "TRASTUZUMAB", "TRASTUZUMAB DERUXTECAN", "TRASTUZUMAB DUOCARMAZINE", "TRASTUZUMAB EMTANSINE", "TUCATINIB", "VANDETANIB", "ZANIDATAMAB", "ZENOCUTUZUMAB" ], "n_approved": 17, "approved_for": { "AFATINIB": [ "non-small cell lung carcinoma" ], "AFATINIB DIMALEATE": [ "non-small cell lung carcinoma" ], "DACOMITINIB": [ "non-small cell lung carcinoma" ], "LAPATINIB": [ "breast cancer" ], "LAPATINIB DITOSYLATE": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "MARGETUXIMAB": [ "HER2 positive breast carcinoma", "breast cancer" ], "MASOPROCOL": [ "prostate cancer" ], "NERATINIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "PERTUZUMAB": [ "breast cancer", "breast carcinoma", "breast neoplasm" ], "TRASTUZUMAB": [ "breast cancer", "breast carcinoma", "gastric cancer", "gastric neoplasm", "breast neoplasm" ], "TRASTUZUMAB DERUXTECAN": [ "breast cancer", "HER2 positive breast carcinoma", "breast neoplasm" ], "TRASTUZUMAB DUOCARMAZINE": [], "TRASTUZUMAB EMTANSINE": [ "breast cancer", "breast carcinoma", "breast neoplasm" ], "TUCATINIB": [ "HER2 positive breast carcinoma", "metastasis", "breast neoplasm", "breast cancer", "colorectal carcinoma", "breast carcinoma" ], "VANDETANIB": [ "thyroid gland carcinoma", "medullary thyroid gland carcinoma", "thyroid tumor" ], "ZANIDATAMAB": [ "biliary tract neoplasm" ], "ZENOCUTUZUMAB": [ "non-small cell lung carcinoma", "pancreatic neoplasm" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Approved Drug" } ] }, { "symbol": "CD274", "ensembl": "ENSG00000120217", "n_drug_entries": 13, "n_distinct_drugs": 13, "drugs": { "ADEBRELIMAB": "PHASE_3", "ATEZOLIZUMAB": "APPROVAL", "AVELUMAB": "APPROVAL", "BINTRAFUSP ALFA": "PHASE_3", "COSIBELIMAB": "APPROVAL", "DANBURSTOTUG": "PHASE_2", "DURVALUMAB": "APPROVAL", "ENVAFOLIMAB": "PHASE_3", "ERFONRILIMAB": "PHASE_3", "INCB-086550": "PHASE_2", "PACMILIMAB": "PHASE_2", "SOCAZOLIMAB": "PHASE_3", "SUGEMALIMAB": "APPROVAL" }, "approved": [ "ATEZOLIZUMAB", "AVELUMAB", "COSIBELIMAB", "DURVALUMAB", "SUGEMALIMAB" ], "n_approved": 5, "approved_for": { "ATEZOLIZUMAB": [ "urothelial carcinoma", "non-small cell lung carcinoma", "breast cancer", "small cell lung carcinoma", "breast neoplasm", "transitional cell carcinoma" ], "AVELUMAB": [ "Merkel cell skin cancer", "urothelial carcinoma", "neuroendocrine neoplasm" ], "COSIBELIMAB": [ "head and neck squamous cell carcinoma" ], "DURVALUMAB": [ "non-small cell lung carcinoma", "small cell lung carcinoma", "urothelial carcinoma", "hepatocellular carcinoma" ], "SUGEMALIMAB": [ "non-small cell lung carcinoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "PDCD1", "ensembl": "ENSG00000188389", "n_drug_entries": 26, "n_distinct_drugs": 26, "drugs": { "APL-501": "PHASE_2", "BALSTILIMAB": "PHASE_3", "BUDIGALIMAB": "PHASE_2_3", "CADONILIMAB": "PHASE_3", "CAMRELIZUMAB": "PHASE_3", "CEMIPLIMAB": "APPROVAL", "CETRELIMAB": "PHASE_3", "CS-1003": "PHASE_3", "DOSTARLIMAB": "APPROVAL", "FINOTONLIMAB": "PHASE_3", "LOMVASTOMIG": "PHASE_2", "NIVOLUMAB": "APPROVAL", "PEMBROLIZUMAB": "APPROVAL", "PENPULIMAB": "PHASE_3", "PIDILIZUMAB": "PHASE_2", "PIMIVALIMAB": "PHASE_2", "PUCOTENLIMAB": "PHASE_3", "RETIFANLIMAB": "APPROVAL", "SASANLIMAB": "PHASE_3", "SERPLULIMAB": "APPROVAL", "SINTILIMAB": "APPROVAL", "SPARTALIZUMAB": "PHASE_3", "TEBOTELIMAB": "PHASE_2_3", "TISLELIZUMAB": "APPROVAL", "TORIPALIMAB": "APPROVAL", "ZIMBERELIMAB": "PHASE_3" }, "approved": [ "CEMIPLIMAB", "DOSTARLIMAB", "NIVOLUMAB", "PEMBROLIZUMAB", "RETIFANLIMAB", "SERPLULIMAB", "SINTILIMAB", "TISLELIZUMAB", "TORIPALIMAB" ], "n_approved": 9, "approved_for": { "CEMIPLIMAB": [ "squamous cell carcinoma", "basal cell carcinoma", "cutaneous squamous cell carcinoma", "cervical cancer" ], "DOSTARLIMAB": [ "endometrial cancer", "endometrial neoplasm" ], "NIVOLUMAB": [ "head and neck cancer", "pleural mesothelioma", "gastric cancer", "melanoma", "non-small cell lung carcinoma", "renal cell carcinoma", "transitional cell carcinoma", "colorectal neoplasm", "Hodgkins lymphoma", "mesothelioma", "head and neck squamous cell carcinoma", "classic Hodgkin lymphoma", "metastatic melanoma" ], "PEMBROLIZUMAB": [ "melanoma", "metastatic melanoma", "endometrium neoplasm", "head and neck squamous cell carcinoma", "transitional cell carcinoma", "renal cell carcinoma", "Hodgkins lymphoma", "non-small cell lung carcinoma" ], "RETIFANLIMAB": [ "neuroendocrine carcinoma", "Merkel cell skin cancer", "squamous cell carcinoma" ], "SERPLULIMAB": [ "esophageal squamous cell carcinoma", "non-small cell lung carcinoma", "small cell lung carcinoma" ], "SINTILIMAB": [ "Hodgkins lymphoma" ], "TISLELIZUMAB": [ "esophageal cancer", "Hodgkins lymphoma", "non-small cell lung carcinoma", "adenocarcinoma", "esophageal squamous cell carcinoma", "gastric neoplasm" ], "TORIPALIMAB": [ "melanoma", "nasopharyngeal carcinoma", "urothelial carcinoma", "esophageal squamous cell carcinoma", "Niemann-Pick disease type B" ] }, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "CDKN2A", "ensembl": "ENSG00000147889", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [] }, { "symbol": "NFE2L2", "ensembl": "ENSG00000116044", "n_drug_entries": 2, "n_distinct_drugs": 2, "drugs": { "BARDOXOLONE METHYL": "PHASE_3", "OMAVELOXOLONE": "APPROVAL" }, "approved": [ "OMAVELOXOLONE" ], "n_approved": 1, "approved_for": { "OMAVELOXOLONE": [] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "SOX2", "ensembl": "ENSG00000181449", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" } ] }, { "symbol": "EGFR", "ensembl": "ENSG00000146648", "n_drug_entries": 82, "n_distinct_drugs": 74, "drugs": { "ABIVERTINIB": "PHASE_3", "AC-480": "PHASE_2", "AEE-788": "PHASE_1_2", "AFATINIB": "APPROVAL", "AFATINIB DIMALEATE": "APPROVAL", "ALLITINIB": "PHASE_1", "AMIVANTAMAB": "APPROVAL", "AUMOLERTINIB": "APPROVAL", "AV-412": "PHASE_1", "AZD-3759": "PHASE_2_3", "AZD-4769": "PHASE_1", "BAFISONTAMAB": "PHASE_2", "BMS-690514": "PHASE_2", "BRIGATINIB": "APPROVAL", "CANERTINIB": "PHASE_2", "CEP-32496": "PHASE_1_2", "CETUXIMAB": "APPROVAL", "CETUXIMAB SAROTALOCAN": "APPROVAL", "CLN-081": "PHASE_3", "CUDC-101": "PHASE_1", "DACOMITINIB": "APPROVAL", "DEPATUXIZUMAB": "PHASE_2", "DEPATUXIZUMAB MAFODOTIN": "PHASE_3", "DULIGOTUZUMAB": "PHASE_2", "EPITINIB": "PHASE_1", "ERLOTINIB": "APPROVAL", "FALNIDAMOL": "PHASE_1", "FIRMONERTINIB": "PHASE_3", "FUTUXIMAB": "PHASE_3", "GC1118": "PHASE_2", "GEFITINIB": "APPROVAL", "ICOTINIB": "APPROVAL", "IMGATUZUMAB": "PHASE_2", "JNJ-26483327": "PHASE_1", "KBP5209": "PHASE_1", "LAPATINIB": "APPROVAL", "LAPATINIB DITOSYLATE": "APPROVAL", "LAZERTINIB": "APPROVAL", "LOSATUXIZUMAB VEDOTIN": "PHASE_1", "MAB-425": "UNKNOWN", "MATUZUMAB": "PHASE_2", "MAVELERTINIB": "PHASE_1_2", "MDX-447": "PHASE_1", "MOBOCERTINIB": "APPROVAL", "MODOTUXIMAB": "PHASE_2", "NAQUOTINIB": "PHASE_3", "NAZARTINIB": "PHASE_3", "NECITUMUMAB": "APPROVAL", "NERATINIB": "APPROVAL", "NIMOTUZUMAB": "APPROVAL", "OLMUTINIB": "APPROVAL", "OSIMERTINIB": "APPROVAL", "PANITUMUMAB": "APPROVAL", "PELITINIB": "PHASE_2", "PF-06459988": "PHASE_2", "PIMURUTAMAB": "PHASE_2_3", "PKI-166": "PHASE_2", "POZIOTINIB": "PHASE_3", "PYROTINIB": "PHASE_3", "RINDOPEPIMUT": "PHASE_3", "ROCILETINIB": "APPROVAL", "RUSERONTINIB": "PHASE_3", "S-222611": "PHASE_1", "SAPITINIB": "PHASE_2", "SIMOTINIB": "PHASE_1", "TAK-285": "PHASE_1", "TARLOXOTINIB": "PHASE_2", "TESEVATINIB": "PHASE_3", "THELIATINIB": "PHASE_1", "TOMUZOTUXIMAB": "PHASE_2", "TUXOBERTINIB": "PHASE_1_2", "VANDETANIB": "APPROVAL", "VARLITINIB": "PHASE_2_3", "ZALUTUMUMAB": "PHASE_3" }, "approved": [ "AFATINIB", "AFATINIB DIMALEATE", "AMIVANTAMAB", "AUMOLERTINIB", "BRIGATINIB", "CETUXIMAB", "CETUXIMAB SAROTALOCAN", "DACOMITINIB", "ERLOTINIB", "GEFITINIB", "ICOTINIB", "LAPATINIB", "LAPATINIB DITOSYLATE", "LAZERTINIB", "MOBOCERTINIB", "NECITUMUMAB", "NERATINIB", "NIMOTUZUMAB", "OLMUTINIB", "OSIMERTINIB", "PANITUMUMAB", "ROCILETINIB", "VANDETANIB" ], "n_approved": 23, "approved_for": { "AFATINIB": [ "non-small cell lung carcinoma" ], "AFATINIB DIMALEATE": [ "non-small cell lung carcinoma" ], "AMIVANTAMAB": [ "non-small cell lung carcinoma" ], "AUMOLERTINIB": [ "non-small cell lung carcinoma" ], "BRIGATINIB": [ "non-small cell lung carcinoma", "anaplastic large cell lymphoma" ], "CETUXIMAB": [ "malignant tumor of neck", "squamous cell carcinoma", "colorectal adenocarcinoma", "colorectal carcinoma", "colorectal cancer", "head and neck neoplasm", "colorectal neoplasm" ], "CETUXIMAB SAROTALOCAN": [ "head and neck cancer" ], "DACOMITINIB": [ "non-small cell lung carcinoma" ], "ERLOTINIB": [ "non-small cell lung carcinoma", "pancreatic neoplasm" ], "GEFITINIB": [ "non-small cell lung carcinoma", "head and neck squamous cell carcinoma" ], "ICOTINIB": [], "LAPATINIB": [ "breast cancer" ], "LAPATINIB DITOSYLATE": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "LAZERTINIB": [ "non-small cell lung carcinoma" ], "MOBOCERTINIB": [ "non-small cell lung carcinoma" ], "NECITUMUMAB": [ "non-small cell lung carcinoma", "colorectal cancer", "non-small cell squamous lung carcinoma" ], "NERATINIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "NIMOTUZUMAB": [ "head and neck cancer" ], "OLMUTINIB": [], "OSIMERTINIB": [ "non-small cell lung carcinoma" ], "PANITUMUMAB": [ "colorectal cancer", "colorectal adenocarcinoma", "colorectal neoplasm" ], "ROCILETINIB": [], "VANDETANIB": [ "thyroid gland carcinoma", "medullary thyroid gland carcinoma", "thyroid tumor" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt loc med conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "CCND1", "ensembl": "ENSG00000110092", "n_drug_entries": 2, "n_distinct_drugs": 2, "drugs": { "BRICICLIB": "PHASE_1", "PALBOCICLIB": "APPROVAL" }, "approved": [ "PALBOCICLIB" ], "n_approved": 1, "approved_for": { "PALBOCICLIB": [ "breast cancer", "breast carcinoma", "breast neoplasm" ] }, "tractability": [ { "modality": "SM", "bucket": "Advanced Clinical" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "KRAS", "ensembl": "ENSG00000133703", "n_drug_entries": 3, "n_distinct_drugs": 3, "drugs": { "ADAGRASIB": "APPROVAL", "SALIRASIB": "PHASE_2", "SOTORASIB": "APPROVAL" }, "approved": [ "ADAGRASIB", "SOTORASIB" ], "n_approved": 2, "approved_for": { "ADAGRASIB": [ "non-small cell lung carcinoma" ], "SOTORASIB": [ "non-small cell lung carcinoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "SMAD4", "ensembl": "ENSG00000141646", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" } ] }, { "symbol": "CLDN18", "ensembl": "ENSG00000066405", "n_drug_entries": 1, "n_distinct_drugs": 1, "drugs": { "ZOLBETUXIMAB": "APPROVAL" }, "approved": [ "ZOLBETUXIMAB" ], "n_approved": 1, "approved_for": { "ZOLBETUXIMAB": [ "gastric cancer", "neoplasm of esophagus", "gastric neoplasm", "gastric adenocarcinoma", "gastroesophageal junction adenocarcinoma" ] }, "tractability": [ { "modality": "AB", "bucket": "Advanced Clinical" }, { "modality": "AB", "bucket": "UniProt loc med conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "GO CC med conf" } ] } ], "trials": { "by_antigen": { "PD-1": { "n": 389, "n_observational": 27, "n_active": 189, "n_withdrawn": 8, "trials": [ { "nct": "NCT03526835", "title": "A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03556228", "title": "VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma", "status": "RECRUITING", "last_update": "2025-12-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03736863", "title": "A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04114136", "title": "Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies", "status": "RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04389632", "title": "A Study of Sigvotatug Vedotin in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04592211", "title": "Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer", "status": "RECRUITING", "last_update": "2025-07-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04807673", "title": "Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)", "status": "RECRUITING", "last_update": "2022-06-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04821778", "title": "Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04821843", "title": "Neoadjuvant Treatment Modalities in Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04900818", "title": "Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-03-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04973306", "title": "Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC", "status": "RECRUITING", "last_update": "2022-06-30", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05086692", "title": "A Beta-only IL-2 ImmunoTherapY Study", "status": "RECRUITING", "last_update": "2025-07-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05144698", "title": "RAPA-201 Therapy of Solid Tumors", "status": "RECRUITING", "last_update": "2025-05-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05177133", "title": "Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)", "status": "RECRUITING", "last_update": "2024-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05182944", "title": "A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC", "status": "RECRUITING", "last_update": "2022-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05187182", "title": "CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-04-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05187338", "title": "Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05208762", "title": "A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05267626", "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05319730", "title": "A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05332002", "title": "sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)", "status": "RECRUITING", "last_update": "2026-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05357846", "title": "PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05507411", "title": "Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC", "status": "RECRUITING", "last_update": "2022-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05515315", "title": "Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-02-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05624099", "title": "Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.", "status": "RECRUITING", "last_update": "2023-10-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05677490", "title": "mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05738434", "title": "Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC", "status": "RECRUITING", "last_update": "2024-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05919030", "title": "A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-11-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05937438", "title": "Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma", "status": "RECRUITING", "last_update": "2025-01-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05944237", "title": "HTL0039732 in Participants With Advanced Solid Tumours", "status": "RECRUITING", "last_update": "2025-06-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05954312", "title": "A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05978193", "title": "Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05984342", "title": "Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2023-08-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06006650", "title": "Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell", "status": "RECRUITING", "last_update": "2023-08-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06008054", "title": "A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors", "status": "RECRUITING", "last_update": "2025-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06022861", "title": "A Study to Compare the Efficacy and Safety of LY01015 and Opdivo\u00ae Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-09-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06047379", "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06056336", "title": "Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2023-09-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06061146", "title": "Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC", "status": "RECRUITING", "last_update": "2023-12-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06084897", "title": "Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy", "status": "RECRUITING", "last_update": "2024-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06086457", "title": "PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer", "status": "RECRUITING", "last_update": "2024-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06122493", "title": "Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2023-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06123338", "title": "A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06190782", "title": "Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor", "status": "RECRUITING", "last_update": "2024-05-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06203600", "title": "Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06265285", "title": "Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program", "status": "RECRUITING", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06304350", "title": "Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06339060", "title": "An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).", "status": "RECRUITING", "last_update": "2024-07-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06354140", "title": "PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY", "status": "RECRUITING", "last_update": "2024-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06354530", "title": "A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-04-09", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06385730", "title": "Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)", "status": "RECRUITING", "last_update": "2024-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06422403", "title": "A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers", "status": "RECRUITING", "last_update": "2025-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06430658", "title": "Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer", "status": "RECRUITING", "last_update": "2024-12-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06445972", "title": "Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06446726", "title": "Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06469944", "title": "Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06509568", "title": "Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma\uff08CRIS-2 Trial\uff09", "status": "RECRUITING", "last_update": "2025-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06532799", "title": "TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer", "status": "RECRUITING", "last_update": "2024-11-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06545331", "title": "Study of XB010 in Subjects With Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06646588", "title": "Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-10-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06676449", "title": "TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC", "status": "RECRUITING", "last_update": "2026-01-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06690476", "title": "Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-11-15", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06709417", "title": "A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)", "status": "RECRUITING", "last_update": "2024-11-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06773507", "title": "Phase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-07-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06780111", "title": "Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06869226", "title": "A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer", "status": "RECRUITING", "last_update": "2025-10-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06907602", "title": "Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-04-02", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06964568", "title": "CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC", "status": "RECRUITING", "last_update": "2026-04-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07000253", "title": "Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07016724", "title": "Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer", "status": "RECRUITING", "last_update": "2025-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07039162", "title": "Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07059299", "title": "A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma", "status": "RECRUITING", "last_update": "2025-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07061704", "title": "Oncolytic Virus in Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-12-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07071103", "title": "Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors", "status": "RECRUITING", "last_update": "2025-11-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07152678", "title": "Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07162506", "title": "DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI", "status": "RECRUITING", "last_update": "2026-05-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07205731", "title": "Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma", "status": "RECRUITING", "last_update": "2026-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07221149", "title": "A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07223424", "title": "Patient Preference for Subcutaneous vs. Intravenous Immune Therapy", "status": "RECRUITING", "last_update": "2026-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07227168", "title": "A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07272382", "title": "Omega-3 Fatty Acids With PD-1 Inhibitors in Advanced Esophageal Cancer", "status": "RECRUITING", "last_update": "2025-12-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07290010", "title": "The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07317609", "title": "Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)", "status": "RECRUITING", "last_update": "2026-01-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07334119", "title": "Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07339488", "title": "Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07367516", "title": "Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-07-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07392892", "title": "Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07403136", "title": "Becotatug Vedotin \u00b1 Anti-PD-1 in Pretreated Advanced ESCC", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07405151", "title": "A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07410676", "title": "EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 \u00b1 Pembrolizumab in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-02-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07431281", "title": "Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07432295", "title": "Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)", "status": "RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07455019", "title": "A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07481058", "title": "KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07518043", "title": "A Study of HLX18 vs. OPDIVO\u00ae in Multiple Resected Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07530094", "title": "Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07554456", "title": "A Study of BL-B01D1 in Combination With Tislelizumab \u00b15-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07554521", "title": "A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07559045", "title": "Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07629817", "title": "Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy", "status": "RECRUITING", "last_update": "2026-07-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07700667", "title": "SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07730021", "title": "A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07749586", "title": "A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07751055", "title": "Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07811752", "title": "Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02013154", "title": "A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab", "status": "COMPLETED", "last_update": "2025-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02213289", "title": "PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression", "status": "COMPLETED", "last_update": "2021-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02318901", "title": "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer", "status": "TERMINATED", "last_update": "2019-10-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02559687", "title": "Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)", "status": "COMPLETED", "last_update": "2022-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02564263", "title": "Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)", "status": "COMPLETED", "last_update": "2023-03-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02569242", "title": "Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer", "status": "COMPLETED", "last_update": "2022-07-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02635672", "title": "Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer", "status": "COMPLETED", "last_update": "2024-11-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02642809", "title": "Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers", "status": "COMPLETED", "last_update": "2026-03-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02689284", "title": "Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2025-03-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02735239", "title": "Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer", "status": "COMPLETED", "last_update": "2024-03-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02743494", "title": "An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2025-11-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02757391", "title": "CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors", "status": "TERMINATED", "last_update": "2020-10-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02830594", "title": "Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2024-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02834013", "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02844075", "title": "Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29)", "status": "COMPLETED", "last_update": "2024-11-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02872116", "title": "Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer", "status": "COMPLETED", "last_update": "2025-08-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02915432", "title": "The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC", "status": "UNKNOWN", "last_update": "2021-12-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02946671", "title": "Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients", "status": "COMPLETED", "last_update": "2020-03-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02954536", "title": "Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer", "status": "COMPLETED", "last_update": "2023-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02971956", "title": "Pembrolizumab in Refractory Advanced Esophageal Cancer", "status": "COMPLETED", "last_update": "2023-09-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03044613", "title": "Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03064490", "title": "Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)", "status": "COMPLETED", "last_update": "2025-04-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03081715", "title": "PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer", "status": "COMPLETED", "last_update": "2019-06-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03099382", "title": "Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer", "status": "COMPLETED", "last_update": "2024-01-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03122548", "title": "Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers", "status": "TERMINATED", "last_update": "2019-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03126110", "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies", "status": "COMPLETED", "last_update": "2025-08-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03143153", "title": "A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin", "status": "COMPLETED", "last_update": "2026-02-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03187314", "title": "Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer", "status": "COMPLETED", "last_update": "2020-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03189719", "title": "First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)", "status": "COMPLETED", "last_update": "2024-10-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03196232", "title": "Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer", "status": "COMPLETED", "last_update": "2024-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03200691", "title": "Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2017-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03220009", "title": "Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma", "status": "WITHDRAWN", "last_update": "2018-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03222440", "title": "Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC", "status": "COMPLETED", "last_update": "2019-12-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03233724", "title": "Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas", "status": "TERMINATED", "last_update": "2023-05-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03236935", "title": "Phase Ib of L-NMMA and Pembrolizumab", "status": "COMPLETED", "last_update": "2026-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03241173", "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies", "status": "COMPLETED", "last_update": "2022-09-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03277352", "title": "INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies", "status": "TERMINATED", "last_update": "2021-07-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03278626", "title": "Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2022-03-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03292250", "title": "Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]", "status": "COMPLETED", "last_update": "2022-03-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03322267", "title": "Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence", "status": "COMPLETED", "last_update": "2026-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03329950", "title": "A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies", "status": "COMPLETED", "last_update": "2024-03-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03342937", "title": "KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer", "status": "COMPLETED", "last_update": "2024-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03365791", "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies", "status": "COMPLETED", "last_update": "2022-05-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03395847", "title": "Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma", "status": "COMPLETED", "last_update": "2023-11-18", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03409848", "title": "Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma", "status": "COMPLETED", "last_update": "2022-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03416244", "title": "A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer", "status": "COMPLETED", "last_update": "2022-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03430843", "title": "A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2024-10-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03469557", "title": "BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma", "status": "COMPLETED", "last_update": "2024-10-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03474640", "title": "Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies", "status": "COMPLETED", "last_update": "2024-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03488667", "title": "Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2023-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03505320", "title": "A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544723", "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.", "status": "UNKNOWN", "last_update": "2020-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544736", "title": "Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2023-03-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03592407", "title": "Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer", "status": "WITHDRAWN", "last_update": "2022-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03603756", "title": "SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer", "status": "UNKNOWN", "last_update": "2020-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03621982", "title": "Study of ADCT-301 in Patients With Selected Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-06-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03671265", "title": "Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC", "status": "UNKNOWN", "last_update": "2019-01-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03691090", "title": "Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer", "status": "COMPLETED", "last_update": "2022-12-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03697824", "title": "Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a", "status": "WITHDRAWN", "last_update": "2019-10-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03706326", "title": "CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer", "status": "UNKNOWN", "last_update": "2018-10-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03708328", "title": "A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2025-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03709706", "title": "Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab", "status": "TERMINATED", "last_update": "2024-02-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03748134", "title": "Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )", "status": "COMPLETED", "last_update": "2023-10-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03764553", "title": "Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03766178", "title": "Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2021-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03783442", "title": "A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2025-07-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03792347", "title": "Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus", "status": "COMPLETED", "last_update": "2023-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03809624", "title": "Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer", "status": "TERMINATED", "last_update": "2024-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03811379", "title": "Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy", "status": "UNKNOWN", "last_update": "2019-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03817658", "title": "A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC", "status": "UNKNOWN", "last_update": "2019-01-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03881111", "title": "First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study", "status": "WITHDRAWN", "last_update": "2020-02-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03914443", "title": "A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma", "status": "COMPLETED", "last_update": "2025-05-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03933449", "title": "Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study", "status": "COMPLETED", "last_update": "2023-03-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03940001", "title": "A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer", "status": "UNKNOWN", "last_update": "2019-09-09", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03946969", "title": "Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer", "status": "UNKNOWN", "last_update": "2022-07-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03957590", "title": "A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2026-04-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03958890", "title": "A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)", "status": "UNKNOWN", "last_update": "2023-04-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03987815", "title": "Neoadjuvant Nivolumab for Operable Esophageal Carcinoma", "status": "UNKNOWN", "last_update": "2020-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03993353", "title": "Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2026-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03995017", "title": "Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma", "status": "UNKNOWN", "last_update": "2023-02-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04000529", "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies", "status": "TERMINATED", "last_update": "2025-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04005170", "title": "Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer", "status": "COMPLETED", "last_update": "2022-08-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04032704", "title": "A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04041310", "title": "Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04044859", "title": "ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04060342", "title": "GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma", "status": "TERMINATED", "last_update": "2022-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04062656", "title": "Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG", "status": "UNKNOWN", "last_update": "2024-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04084158", "title": "A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.", "status": "SUSPENDED", "last_update": "2021-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04116320", "title": "Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04140500", "title": "Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04140526", "title": "Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04152018", "title": "Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.", "status": "TERMINATED", "last_update": "2025-05-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04171141", "title": "Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.", "status": "TERMINATED", "last_update": "2025-01-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04177875", "title": "Neoadjuvant Chemoradiotherapy Combined With PD-1 Antibody in Locally Advanced Esophageal Cancer", "status": "UNKNOWN", "last_update": "2019-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04187872", "title": "LITT and Pembrolizumab in Recurrent Brain Metastasis", "status": "TERMINATED", "last_update": "2023-12-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04195373", "title": "A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract", "status": "WITHDRAWN", "last_update": "2020-11-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04196465", "title": "Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04210115", "title": "Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)", "status": "COMPLETED", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04225117", "title": "A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04225364", "title": "Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2021-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04229459", "title": "Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04242199", "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04244552", "title": "A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies", "status": "TERMINATED", "last_update": "2023-12-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04272034", "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-10-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04286958", "title": "A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC", "status": "UNKNOWN", "last_update": "2021-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379596", "title": "Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04389177", "title": "Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)", "status": "UNKNOWN", "last_update": "2023-04-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04390945", "title": "Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer", "status": "UNKNOWN", "last_update": "2022-02-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04404491", "title": "Clinical Control Study of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer Recurrence", "status": "UNKNOWN", "last_update": "2020-05-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04426955", "title": "Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer", "status": "UNKNOWN", "last_update": "2021-09-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04430738", "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04435197", "title": "Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2024-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04458259", "title": "Study of PF-07265807 in Participants With Metastatic Solid Tumors.", "status": "TERMINATED", "last_update": "2026-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04471480", "title": "TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer", "status": "UNKNOWN", "last_update": "2020-07-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04494009", "title": "PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04503967", "title": "Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer", "status": "UNKNOWN", "last_update": "2020-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04506138", "title": "Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2021-12-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04508140", "title": "Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis", "status": "TERMINATED", "last_update": "2024-11-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04510285", "title": "A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection", "status": "TERMINATED", "last_update": "2023-02-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04510818", "title": "Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2)", "status": "UNKNOWN", "last_update": "2020-08-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04512417", "title": "A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer", "status": "UNKNOWN", "last_update": "2020-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04594811", "title": "NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma", "status": "TERMINATED", "last_update": "2024-08-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04625543", "title": "Neoadjuvant Immunotherapy to ESCC", "status": "WITHDRAWN", "last_update": "2022-04-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04641871", "title": "Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies", "status": "COMPLETED", "last_update": "2024-06-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04654403", "title": "Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer", "status": "UNKNOWN", "last_update": "2021-08-23", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04672434", "title": "Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies", "status": "COMPLETED", "last_update": "2024-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04704154", "title": "A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors", "status": "COMPLETED", "last_update": "2025-04-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04721223", "title": "JAB-3068 Activity in Adult Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04732494", "title": "Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2025-01-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04757363", "title": "A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04767295", "title": "A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)", "status": "UNKNOWN", "last_update": "2021-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04776590", "title": "Chemoradiotherapy Plus Immunotherapy Followed by Surgery for Esophageal Cancer", "status": "UNKNOWN", "last_update": "2024-04-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04779151", "title": "Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab", "status": "TERMINATED", "last_update": "2025-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04785820", "title": "A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus", "status": "COMPLETED", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04797507", "title": "SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer", "status": "UNKNOWN", "last_update": "2021-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04802876", "title": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04819971", "title": "Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC", "status": "UNKNOWN", "last_update": "2023-04-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04821765", "title": "Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer", "status": "COMPLETED", "last_update": "2025-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04866381", "title": "An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody", "status": "UNKNOWN", "last_update": "2021-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04879368", "title": "RegoNivo vs Standard of Care Chemotherapy in AGOC", "status": "COMPLETED", "last_update": "2026-06-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04913337", "title": "Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies", "status": "UNKNOWN", "last_update": "2024-10-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04925284", "title": "Study of XB002 in Subjects With Solid Tumors (JEWEL-101)", "status": "COMPLETED", "last_update": "2025-04-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04929392", "title": "Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04949256", "title": "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).", "status": "TERMINATED", "last_update": "2026-08-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04984018", "title": "Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade", "status": "UNKNOWN", "last_update": "2021-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04984733", "title": "Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer", "status": "COMPLETED", "last_update": "2026-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05007106", "title": "MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)", "status": "COMPLETED", "last_update": "2025-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05007145", "title": "PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2021-12-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05044728", "title": "Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest.", "status": "UNKNOWN", "last_update": "2021-09-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05049681", "title": "Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell", "status": "UNKNOWN", "last_update": "2021-09-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05050760", "title": "DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer", "status": "UNKNOWN", "last_update": "2023-01-31", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05053295", "title": "Investigator-initiated Pilot Study to Investigate the Efficacy and Safety of Immuncell-LC in Combination With Nivolumab (Opdivo) in Subjects With Advanced or Recurrent Gastric Cancer", "status": "UNKNOWN", "last_update": "2021-09-22", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05070247", "title": "A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2026-01-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05104567", "title": "A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)", "status": "COMPLETED", "last_update": "2025-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05152147", "title": "A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05163483", "title": "Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer", "status": "UNKNOWN", "last_update": "2023-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05170256", "title": "Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients", "status": "UNKNOWN", "last_update": "2022-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05170542", "title": "The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.", "status": "UNKNOWN", "last_update": "2021-12-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05174156", "title": "Study on the Biomarker of First-line Immunotherapy Combined With Chemotherapy in Advanced Esophageal Cancer", "status": "UNKNOWN", "last_update": "2022-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05174325", "title": "Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2021-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05176002", "title": "Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05183958", "title": "A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer", "status": "UNKNOWN", "last_update": "2022-01-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05184946", "title": "Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction Adenocarcinoma", "status": "UNKNOWN", "last_update": "2022-01-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05192460", "title": "Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer, Esophageal Cancer and Liver Cancer", "status": "UNKNOWN", "last_update": "2023-03-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05213312", "title": "Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC", "status": "UNKNOWN", "last_update": "2022-06-15", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05215574", "title": "Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05245760", "title": "ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer", "status": "WITHDRAWN", "last_update": "2022-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05265962", "title": "Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade", "status": "UNKNOWN", "last_update": "2022-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05281003", "title": "Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)", "status": "UNKNOWN", "last_update": "2023-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05302011", "title": "Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2023-10-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05311618", "title": "Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors", "status": "UNKNOWN", "last_update": "2024-04-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05322499", "title": "Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer", "status": "UNKNOWN", "last_update": "2022-04-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05323890", "title": "Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.", "status": "UNKNOWN", "last_update": "2023-03-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05329766", "title": "A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05342636", "title": "A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)", "status": "COMPLETED", "last_update": "2025-12-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05355168", "title": "Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma", "status": "COMPLETED", "last_update": "2024-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05386056", "title": "Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2022-11-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05394415", "title": "Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC", "status": "UNKNOWN", "last_update": "2022-05-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05424432", "title": "Short Course Neoadjuvant Chemo-radiotherapy Plus Toripalimab for Locally Advanced Resectble Squamous Cell Carcinoma of Esophagus", "status": "UNKNOWN", "last_update": "2022-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05438420", "title": "Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05461794", "title": "Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2025-06-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05469061", "title": "Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC", "status": "UNKNOWN", "last_update": "2022-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05476380", "title": "Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2022-07-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05476796", "title": "Oxaliplatin \u00b1 Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05480384", "title": "Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05490719", "title": "A Phase II Study of CRT Combined With QL1706 in ESCC Patients", "status": "UNKNOWN", "last_update": "2024-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05491616", "title": "Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05512520", "title": "Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma\uff08EC-CRT-003\uff09", "status": "UNKNOWN", "last_update": "2023-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05520619", "title": "Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05522894", "title": "AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC", "status": "UNKNOWN", "last_update": "2022-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05541445", "title": "Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC", "status": "UNKNOWN", "last_update": "2022-09-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05544929", "title": "A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05568095", "title": "A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body", "status": "COMPLETED", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05572684", "title": "A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2026-08-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05581004", "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05596890", "title": "Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients", "status": "UNKNOWN", "last_update": "2022-11-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05603065", "title": "Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TINES)", "status": "UNKNOWN", "last_update": "2023-06-29", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05621707", "title": "Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05626569", "title": "Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC", "status": "UNKNOWN", "last_update": "2024-01-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05628610", "title": "Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05637268", "title": "Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2022-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05650216", "title": "Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC\uff08NICE-RT\uff09", "status": "UNKNOWN", "last_update": "2022-12-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05708950", "title": "A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)", "status": "COMPLETED", "last_update": "2026-06-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05714553", "title": "NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours", "status": "TERMINATED", "last_update": "2026-07-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05732662", "title": "SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC", "status": "NOT_YET_RECRUITING", "last_update": "2023-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05737563", "title": "PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC", "status": "UNKNOWN", "last_update": "2024-01-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05760391", "title": "A Study of IO Plus Radiotherapy in Patients With Advanced ESCC.", "status": "UNKNOWN", "last_update": "2023-07-25", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05777707", "title": "Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05788484", "title": "A Study of CDX-585 in Patients With Advanced Malignancies", "status": "COMPLETED", "last_update": "2025-06-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05791136", "title": "Immunotherapy After Radiotherapy in Elderly ESCC", "status": "UNKNOWN", "last_update": "2023-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05807542", "title": "Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC", "status": "COMPLETED", "last_update": "2024-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05821452", "title": "Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma", "status": "UNKNOWN", "last_update": "2023-04-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05829057", "title": "The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1", "status": "UNKNOWN", "last_update": "2024-02-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05830240", "title": "A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer", "status": "UNKNOWN", "last_update": "2023-04-26", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05858736", "title": "Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05880082", "title": "PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer", "status": "COMPLETED", "last_update": "2025-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05898828", "title": "Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer", "status": "WITHDRAWN", "last_update": "2024-08-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05945823", "title": "Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05990231", "title": "Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy", "status": "UNKNOWN", "last_update": "2023-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06010212", "title": "Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2023-08-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06010303", "title": "A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2026-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06034860", "title": "Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types", "status": "TERMINATED", "last_update": "2024-11-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06048926", "title": "Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma", "status": "ENROLLING_BY_INVITATION", "last_update": "2023-09-21", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06055166", "title": "A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors", "status": "UNKNOWN", "last_update": "2023-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06078657", "title": "IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)", "status": "UNKNOWN", "last_update": "2023-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06116136", "title": "A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06184841", "title": "HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2023-12-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06231680", "title": "Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)", "status": "UNKNOWN", "last_update": "2024-03-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06250036", "title": "Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer", "status": "SUSPENDED", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06251973", "title": "A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06303583", "title": "Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma", "status": "ENROLLING_BY_INVITATION", "last_update": "2024-03-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06304974", "title": "A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06342167", "title": "Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06349044", "title": "A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.", "status": "UNKNOWN", "last_update": "2024-08-27", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06401447", "title": "TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06469060", "title": "Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06498752", "title": "MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer", "status": "UNKNOWN", "last_update": "2024-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06585488", "title": "A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification", "status": "TERMINATED", "last_update": "2026-07-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06607185", "title": "A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06654297", "title": "Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06682806", "title": "A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation", "status": "TERMINATED", "last_update": "2026-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06692270", "title": "Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06703047", "title": "Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06728657", "title": "Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma", "status": "SUSPENDED", "last_update": "2025-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06745193", "title": "A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06746961", "title": "Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06748872", "title": "EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06762158", "title": "NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06888531", "title": "Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06914011", "title": "Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06914687", "title": "Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06963593", "title": "Clinical Study on the Treatment of Anorexia and Cachexia in Advanced Gastric and Esophageal Cancer With Nanosized Megestrol Acetate Combined With Immunochemotherapy", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-09", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06965829", "title": "The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06990178", "title": "Adaptive Neoadjuvant Therapy for Esophageal Cancer", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-05-25", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07015489", "title": "Concurrent Radiotherapy Following Induction Chemoimmunotherapy for Locally Advanced Esophageal Cancer", "status": "COMPLETED", "last_update": "2025-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07016737", "title": "Immunochemotherapy \u00b1 Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-06-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07019181", "title": "Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07046221", "title": "Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07049185", "title": "QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07067450", "title": "Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-16", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07128693", "title": "A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07154108", "title": "Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07191405", "title": "Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07191977", "title": "Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07196384", "title": "Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CW", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07218003", "title": "A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07236320", "title": "Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC", "status": "COMPLETED", "last_update": "2025-11-19", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07244978", "title": "Neoadjuvant Ivonescimab\uff08AK112\uff09 Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07251062", "title": "A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-26", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07312578", "title": "Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy\uff08nCT\uff09 in the Treatment of Esophageal Squamous Cell Carcinoma", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07385664", "title": "Neoadjuvant Chemoimmunotherapy or Chemoradiotherapy in ESCC", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07505186", "title": "Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07623642", "title": "A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07653451", "title": "Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07678580", "title": "Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07686926", "title": "Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07688291", "title": "A Phase II Study of PD-1/IL-2\u03b1-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07721103", "title": "Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07733180", "title": "A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07770100", "title": "Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07807345", "title": "Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 6, "n_observational": 0, "n_active": 1, "n_withdrawn": 1, "trials": [ { "nct": "NCT07410676", "title": "EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 \u00b1 Pembrolizumab in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-02-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02757391", "title": "CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors", "status": "TERMINATED", "last_update": "2020-10-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03081715", "title": "PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer", "status": "COMPLETED", "last_update": "2019-06-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03697824", "title": "Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a", "status": "WITHDRAWN", "last_update": "2019-10-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03706326", "title": "CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer", "status": "UNKNOWN", "last_update": "2018-10-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03709706", "title": "Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab", "status": "TERMINATED", "last_update": "2024-02-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "PD-1", "nivolumab", "pembrolizumab", "tislelizumab", "camrelizumab" ] }, "PD-L1": { "n": 125, "n_observational": 8, "n_active": 61, "n_withdrawn": 4, "trials": [ { "nct": "NCT03539822", "title": "Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03556228", "title": "VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma", "status": "RECRUITING", "last_update": "2025-12-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04481256", "title": "TGF-\u03b2 And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY", "status": "RECRUITING", "last_update": "2024-07-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04821778", "title": "Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04821843", "title": "Neoadjuvant Treatment Modalities in Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04900818", "title": "Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-03-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04999761", "title": "AB122 Platform Study", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05144698", "title": "RAPA-201 Therapy of Solid Tumors", "status": "RECRUITING", "last_update": "2025-05-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05187338", "title": "Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05267626", "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05319730", "title": "A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05919030", "title": "A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-11-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05944237", "title": "HTL0039732 in Participants With Advanced Solid Tumours", "status": "RECRUITING", "last_update": "2025-06-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06047379", "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06203600", "title": "Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06272214", "title": "Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy", "status": "RECRUITING", "last_update": "2024-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06290505", "title": "A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06422403", "title": "A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers", "status": "RECRUITING", "last_update": "2025-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06445972", "title": "Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06469944", "title": "Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06601309", "title": "Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC", "status": "RECRUITING", "last_update": "2025-09-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06769113", "title": "A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy", "status": "RECRUITING", "last_update": "2026-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06819566", "title": "Prophylactic Endoscopic Variceal Ligation in Patients With High-risk Esophageal Varices Receiving Atezo/Bev for HCC", "status": "RECRUITING", "last_update": "2025-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06824363", "title": "ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06961526", "title": "Esophageal Varices Prophylaxis in Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab", "status": "RECRUITING", "last_update": "2025-05-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07071103", "title": "Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors", "status": "RECRUITING", "last_update": "2025-11-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07222657", "title": "Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07339488", "title": "Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07367516", "title": "Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-07-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07385001", "title": "A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC", "status": "RECRUITING", "last_update": "2026-02-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07431281", "title": "Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07700420", "title": "Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07733830", "title": "Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01938612", "title": "A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours", "status": "COMPLETED", "last_update": "2021-03-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02213289", "title": "PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression", "status": "COMPLETED", "last_update": "2021-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02520453", "title": "Adjuvant Durvalumab for Esophageal Cancer", "status": "UNKNOWN", "last_update": "2019-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02559687", "title": "Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)", "status": "COMPLETED", "last_update": "2022-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02564263", "title": "Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)", "status": "COMPLETED", "last_update": "2023-03-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02625610", "title": "Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)", "status": "COMPLETED", "last_update": "2022-06-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02639065", "title": "A Study of Durvalumab (MEDI4736) in Esophageal Cancer", "status": "COMPLETED", "last_update": "2023-09-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02658214", "title": "Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2020-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02678182", "title": "Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02735239", "title": "Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer", "status": "COMPLETED", "last_update": "2024-03-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02876510", "title": "ACTolog in Patients With Solid Cancers", "status": "COMPLETED", "last_update": "2025-02-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02962063", "title": "Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03087864", "title": "PDL-1 Targeting in Resectable Oesophageal Cancer", "status": "COMPLETED", "last_update": "2020-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03126110", "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies", "status": "COMPLETED", "last_update": "2025-08-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03174275", "title": "Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03189719", "title": "First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)", "status": "COMPLETED", "last_update": "2024-10-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03212469", "title": "A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer", "status": "COMPLETED", "last_update": "2025-05-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03233724", "title": "Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas", "status": "TERMINATED", "last_update": "2023-05-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03241173", "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies", "status": "COMPLETED", "last_update": "2022-09-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03281369", "title": "A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)", "status": "TERMINATED", "last_update": "2026-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03292250", "title": "Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]", "status": "COMPLETED", "last_update": "2022-03-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03365791", "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies", "status": "COMPLETED", "last_update": "2022-05-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03377400", "title": "Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer", "status": "UNKNOWN", "last_update": "2020-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03386721", "title": "Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2023-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03399071", "title": "Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer", "status": "UNKNOWN", "last_update": "2023-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03421288", "title": "Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03448835", "title": "Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544723", "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.", "status": "UNKNOWN", "last_update": "2020-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03653052", "title": "Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03708328", "title": "A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2025-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03732508", "title": "SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer", "status": "UNKNOWN", "last_update": "2018-11-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03764553", "title": "Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03777813", "title": "Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer", "status": "COMPLETED", "last_update": "2025-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03809624", "title": "Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer", "status": "TERMINATED", "last_update": "2024-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03818997", "title": "Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer", "status": "WITHDRAWN", "last_update": "2020-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03829501", "title": "A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies", "status": "TERMINATED", "last_update": "2025-04-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03881111", "title": "First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study", "status": "WITHDRAWN", "last_update": "2020-02-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03933449", "title": "Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study", "status": "COMPLETED", "last_update": "2023-03-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03959293", "title": "Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma", "status": "UNKNOWN", "last_update": "2024-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03982173", "title": "Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors", "status": "WITHDRAWN", "last_update": "2023-01-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03983954", "title": "Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04054518", "title": "Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2019-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04060342", "title": "GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma", "status": "TERMINATED", "last_update": "2022-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04116320", "title": "Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04159974", "title": "RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus", "status": "UNKNOWN", "last_update": "2024-05-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04166721", "title": "WaKING: Wnt and checKpoint INhibition in Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04196465", "title": "Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04210115", "title": "Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)", "status": "COMPLETED", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04215471", "title": "NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma", "status": "UNKNOWN", "last_update": "2022-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04244552", "title": "A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies", "status": "TERMINATED", "last_update": "2023-12-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379596", "title": "Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04458259", "title": "Study of PF-07265807 in Participants With Metastatic Solid Tumors.", "status": "TERMINATED", "last_update": "2026-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04460066", "title": "A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.", "status": "UNKNOWN", "last_update": "2022-05-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04494009", "title": "PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04540211", "title": "A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma", "status": "COMPLETED", "last_update": "2026-08-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04543617", "title": "A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04550260", "title": "Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04564482", "title": "PD-L1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer", "status": "UNKNOWN", "last_update": "2024-03-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04568200", "title": "Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2024-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04604132", "title": "Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma", "status": "TERMINATED", "last_update": "2024-04-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04625543", "title": "Neoadjuvant Immunotherapy to ESCC", "status": "WITHDRAWN", "last_update": "2022-04-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04713891", "title": "A Study of KF-0210 in Advanced Solid Tumors Patients", "status": "COMPLETED", "last_update": "2024-09-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04732494", "title": "Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2025-01-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04851132", "title": "Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2021-06-22", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04949256", "title": "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).", "status": "TERMINATED", "last_update": "2026-08-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05007106", "title": "MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)", "status": "COMPLETED", "last_update": "2025-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05007613", "title": "Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2025-01-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05038813", "title": "Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)", "status": "UNKNOWN", "last_update": "2023-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05104567", "title": "A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)", "status": "COMPLETED", "last_update": "2025-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05281003", "title": "Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)", "status": "UNKNOWN", "last_update": "2023-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05342636", "title": "A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)", "status": "COMPLETED", "last_update": "2025-12-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05383482", "title": "Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1", "status": "COMPLETED", "last_update": "2025-11-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05386056", "title": "Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2022-11-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05411133", "title": "Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients", "status": "COMPLETED", "last_update": "2026-03-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05450484", "title": "Quantitative Fluorescence Endoscopy Using Durvalumab-680LT in Esophageal Cancer", "status": "COMPLETED", "last_update": "2026-04-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05461794", "title": "Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2025-06-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05581004", "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05667298", "title": "Organ-Preserving Endoscopic Resection & Adjuvant RADIO-immuno-chemotherapy for Esophageal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05713838", "title": "Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05821452", "title": "Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma", "status": "UNKNOWN", "last_update": "2023-04-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06304974", "title": "A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06599775", "title": "Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06690216", "title": "Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-03-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06888531", "title": "Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07191405", "title": "Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07196384", "title": "Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CW", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07565857", "title": "Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07625930", "title": "RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07769866", "title": "Retlirafusp Alfa Combined With Chemoradiotherapy in Unresectable ESCC", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-18", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07770100", "title": "Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "PD-L1", "atezolizumab", "durvalumab" ] }, "HER2": { "n": 100, "n_observational": 13, "n_active": 44, "n_withdrawn": 4, "trials": [ { "nct": "NCT03740256", "title": "Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors", "status": "RECRUITING", "last_update": "2026-02-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04389632", "title": "A Study of Sigvotatug Vedotin in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05187182", "title": "CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-04-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05188313", "title": "TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer", "status": "RECRUITING", "last_update": "2022-06-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05274048", "title": "Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients", "status": "RECRUITING", "last_update": "2025-10-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05332002", "title": "sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)", "status": "RECRUITING", "last_update": "2026-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05427383", "title": "KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy", "status": "RECRUITING", "last_update": "2023-12-19", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05677490", "title": "mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05965479", "title": "Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer", "status": "RECRUITING", "last_update": "2024-11-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05969041", "title": "Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors", "status": "RECRUITING", "last_update": "2024-01-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06084481", "title": "Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06123338", "title": "A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06293898", "title": "Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06324357", "title": "Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06414733", "title": "HER-2 B Cell Peptide Vaccine", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06500052", "title": "A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors", "status": "RECRUITING", "last_update": "2025-09-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06695845", "title": "A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06715839", "title": "Target-specific immunoPET Imaging of Digestive System Carcinoma", "status": "RECRUITING", "last_update": "2025-12-31", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06760819", "title": "A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07000253", "title": "Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07070466", "title": "Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07109726", "title": "A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07334119", "title": "Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07431281", "title": "Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004074", "title": "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu", "status": "COMPLETED", "last_update": "2013-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005842", "title": "Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer", "status": "COMPLETED", "last_update": "2013-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00031681", "title": "7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)", "status": "COMPLETED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00239200", "title": "Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus", "status": "TERMINATED", "last_update": "2008-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00291473", "title": "Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers", "status": "COMPLETED", "last_update": "2009-03-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00447226", "title": "Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists", "status": "TERMINATED", "last_update": "2012-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00450203", "title": "Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer", "status": "UNKNOWN", "last_update": "2016-12-01", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00680901", "title": "LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib", "status": "COMPLETED", "last_update": "2025-08-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01130337", "title": "A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer", "status": "COMPLETED", "last_update": "2015-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01145404", "title": "Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer", "status": "TERMINATED", "last_update": "2014-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01191697", "title": "CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer", "status": "COMPLETED", "last_update": "2025-11-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01196390", "title": "Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer", "status": "COMPLETED", "last_update": "2026-06-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01295086", "title": "Taxotere\u00ae, Eloxatin\u00ae and Xeloda\u00ae (TEX) in Combination With Herceptin\u00ae as Treatment for HER2 Positive Non-resectable Cancer", "status": "COMPLETED", "last_update": "2020-11-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01359397", "title": "Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer", "status": "UNKNOWN", "last_update": "2021-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01364493", "title": "A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer", "status": "COMPLETED", "last_update": "2017-05-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01450696", "title": "A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer", "status": "TERMINATED", "last_update": "2016-11-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01503983", "title": "Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive", "status": "COMPLETED", "last_update": "2015-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01522768", "title": "Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer", "status": "COMPLETED", "last_update": "2023-11-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01579578", "title": "Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer", "status": "TERMINATED", "last_update": "2014-09-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01598077", "title": "A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01613950", "title": "PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer", "status": "COMPLETED", "last_update": "2020-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01614522", "title": "A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2", "status": "COMPLETED", "last_update": "2015-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01705340", "title": "Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery", "status": "TERMINATED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01774851", "title": "A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach", "status": "TERMINATED", "last_update": "2017-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01928290", "title": "Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer", "status": "COMPLETED", "last_update": "2020-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02004769", "title": "Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2016-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02120911", "title": "Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma", "status": "COMPLETED", "last_update": "2020-07-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02205047", "title": "Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma", "status": "COMPLETED", "last_update": "2025-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02205463", "title": "KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer", "status": "WITHDRAWN", "last_update": "2014-08-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02213289", "title": "PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression", "status": "COMPLETED", "last_update": "2021-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02274012", "title": "Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment", "status": "WITHDRAWN", "last_update": "2017-03-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02318901", "title": "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer", "status": "TERMINATED", "last_update": "2019-10-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02344810", "title": "C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer", "status": "WITHDRAWN", "last_update": "2023-05-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02358863", "title": "Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach", "status": "TERMINATED", "last_update": "2018-09-06", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02662348", "title": "T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System", "status": "UNKNOWN", "last_update": "2016-01-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02678182", "title": "Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02689284", "title": "Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2025-03-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02954536", "title": "Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer", "status": "COMPLETED", "last_update": "2023-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03185988", "title": "Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System", "status": "UNKNOWN", "last_update": "2019-07-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03409848", "title": "Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma", "status": "COMPLETED", "last_update": "2022-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03504397", "title": "A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03680560", "title": "Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers", "status": "TERMINATED", "last_update": "2020-03-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03783936", "title": "Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas", "status": "COMPLETED", "last_update": "2023-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03821233", "title": "A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers", "status": "COMPLETED", "last_update": "2025-01-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03929666", "title": "A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer", "status": "COMPLETED", "last_update": "2025-09-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04014075", "title": "DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)", "status": "COMPLETED", "last_update": "2025-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04225117", "title": "A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04248452", "title": "Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379596", "title": "Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04430738", "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04439110", "title": "Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04464967", "title": "Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers", "status": "WITHDRAWN", "last_update": "2021-05-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04467515", "title": "A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer", "status": "TERMINATED", "last_update": "2025-05-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04499924", "title": "Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer", "status": "COMPLETED", "last_update": "2025-01-22", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04510285", "title": "A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection", "status": "TERMINATED", "last_update": "2023-02-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04584008", "title": "Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04604132", "title": "Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma", "status": "TERMINATED", "last_update": "2024-04-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04665921", "title": "A Study of SGN-STNV in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-02-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04704934", "title": "Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04757363", "title": "A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04819971", "title": "Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC", "status": "UNKNOWN", "last_update": "2023-04-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05143970", "title": "A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05152147", "title": "A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05170256", "title": "Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients", "status": "UNKNOWN", "last_update": "2022-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05170542", "title": "The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.", "status": "UNKNOWN", "last_update": "2021-12-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238922", "title": "Study of INCB123667 in Subjects With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05476796", "title": "Oxaliplatin \u00b1 Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05480384", "title": "Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05619016", "title": "[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors", "status": "UNKNOWN", "last_update": "2022-11-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06349044", "title": "A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.", "status": "UNKNOWN", "last_update": "2024-08-27", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06374888", "title": "Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases", "status": "NOT_YET_RECRUITING", "last_update": "2024-04-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07126561", "title": "Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07191405", "title": "Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-24", "phase": "NA", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "HER2", "ERBB2", "trastuzumab", "trastuzumab deruxtecan" ] }, "CLDN18.2": { "n": 12, "n_observational": 3, "n_active": 9, "n_withdrawn": 0, "trials": [ { "nct": "NCT06005493", "title": "Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-02-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06962137", "title": "Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer", "status": "RECRUITING", "last_update": "2025-12-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07000253", "title": "Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07431281", "title": "Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07432295", "title": "Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)", "status": "RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07488676", "title": "A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03504397", "title": "A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03505320", "title": "A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03528629", "title": "A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma", "status": "COMPLETED", "last_update": "2024-12-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04086758", "title": "A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma", "status": "COMPLETED", "last_update": "2024-11-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04683939", "title": "Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors", "status": "TERMINATED", "last_update": "2024-10-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05539430", "title": "Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT05539430", "title": "Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "CLDN18.2", "claudin 18.2", "zolbetuximab" ] }, "EGFR": { "n": 119, "n_observational": 4, "n_active": 37, "n_withdrawn": 6, "trials": [ { "nct": "NCT03526835", "title": "A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740256", "title": "Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors", "status": "RECRUITING", "last_update": "2026-02-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04415853", "title": "Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04821778", "title": "Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04821843", "title": "Neoadjuvant Treatment Modalities in Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05332002", "title": "sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)", "status": "RECRUITING", "last_update": "2026-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05745857", "title": "Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05910827", "title": "A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers", "status": "RECRUITING", "last_update": "2026-05-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06047379", "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06084481", "title": "Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06410651", "title": "Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06429839", "title": "Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients", "status": "RECRUITING", "last_update": "2024-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06715839", "title": "Target-specific immunoPET Imaging of Digestive System Carcinoma", "status": "RECRUITING", "last_update": "2025-12-31", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06718205", "title": "Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06760819", "title": "A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06975410", "title": "Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06988956", "title": "Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-05-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07085091", "title": "A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07181473", "title": "A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-01-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07367516", "title": "Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-07-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07403136", "title": "Becotatug Vedotin \u00b1 Anti-PD-1 in Pretreated Advanced ESCC", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07431281", "title": "Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07457528", "title": "Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC", "status": "RECRUITING", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07660627", "title": "Determining Minimal Residual Disease Using ctDNA Deep Sequencing", "status": "RECRUITING", "last_update": "2026-06-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00096031", "title": "S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2018-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00109850", "title": "S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer", "status": "TERMINATED", "last_update": "2015-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00113581", "title": "Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer", "status": "COMPLETED", "last_update": "2014-02-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00130689", "title": "Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer", "status": "COMPLETED", "last_update": "2015-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00165490", "title": "Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer", "status": "COMPLETED", "last_update": "2014-11-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00183898", "title": "Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00215644", "title": "Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer", "status": "COMPLETED", "last_update": "2018-11-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00239200", "title": "Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus", "status": "TERMINATED", "last_update": "2008-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00319735", "title": "Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas", "status": "COMPLETED", "last_update": "2016-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00381706", "title": "Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2021-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00397384", "title": "Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer", "status": "COMPLETED", "last_update": "2015-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00397904", "title": "Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin", "status": "COMPLETED", "last_update": "2015-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00425425", "title": "Cetuximab, Oxaliplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Esophageal Cancer", "status": "UNKNOWN", "last_update": "2014-05-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00439608", "title": "Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer", "status": "COMPLETED", "last_update": "2020-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00445861", "title": "Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery", "status": "COMPLETED", "last_update": "2012-06-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00509561", "title": "Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer", "status": "UNKNOWN", "last_update": "2012-12-18", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00544362", "title": "Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery", "status": "COMPLETED", "last_update": "2016-05-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00551759", "title": "Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer", "status": "TERMINATED", "last_update": "2023-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00578201", "title": "FOLFOX-Cetuximab-radiotherapy for the Treatment of Esophageal Cancer", "status": "COMPLETED", "last_update": "2011-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00628368", "title": "Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer", "status": "COMPLETED", "last_update": "2026-02-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00636298", "title": "Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy", "status": "WITHDRAWN", "last_update": "2013-11-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00655876", "title": "Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer", "status": "COMPLETED", "last_update": "2022-06-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00678535", "title": "Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer", "status": "COMPLETED", "last_update": "2014-07-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00686114", "title": "Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer", "status": "UNKNOWN", "last_update": "2014-04-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00733889", "title": "A Study to Evaluate the Combination of Cetuximab and Chemotherapy as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy Plus Cetuximab in Locoregional Esophageal Carcinoma", "status": "COMPLETED", "last_update": "2013-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00735345", "title": "Chemotherapy Induction and Chemoradiotherapy in Patients With Esophageal Carcinoma", "status": "TERMINATED", "last_update": "2015-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00757549", "title": "3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx", "status": "COMPLETED", "last_update": "2017-10-31", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00815308", "title": "Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2011-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00827671", "title": "Study of Combination of Cetuximab and Radiotherapy Added to the Standard Treatment for Oesophageal Adenocarcinoma", "status": "TERMINATED", "last_update": "2018-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00950417", "title": "Nimotuzumab in Combination With Chemoradiation for Esophageal Cancer", "status": "COMPLETED", "last_update": "2015-08-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01034189", "title": "Cetuximab/Paclitaxel/Cisplatin Concurrent Chemoradiotherapy Followed by Esophagectomy for Loco-regional Esophageal Cancer", "status": "UNKNOWN", "last_update": "2009-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01107639", "title": "Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery", "status": "COMPLETED", "last_update": "2020-10-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01232374", "title": "Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2015-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01249352", "title": "A Study of Chemoradiation Associated with Nimotuzumab As the Treatment of Locally Advanced Esophageal Cancer", "status": "COMPLETED", "last_update": "2025-03-31", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01336049", "title": "Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer", "status": "UNKNOWN", "last_update": "2011-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01359397", "title": "Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer", "status": "UNKNOWN", "last_update": "2021-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01402180", "title": "Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy", "status": "UNKNOWN", "last_update": "2011-07-26", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01443065", "title": "MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma", "status": "COMPLETED", "last_update": "2020-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01450696", "title": "A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer", "status": "TERMINATED", "last_update": "2016-11-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01463605", "title": "Nimotuzumab Combined With Radiotherapy for Older Patients With Esophageal Cancer: a Single, Non-control Clinical Trial", "status": "COMPLETED", "last_update": "2021-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01486992", "title": "mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus", "status": "UNKNOWN", "last_update": "2012-01-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01561014", "title": "Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction", "status": "COMPLETED", "last_update": "2018-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01614522", "title": "A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2", "status": "COMPLETED", "last_update": "2015-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01688700", "title": "Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2012-09-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01787006", "title": "Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer", "status": "COMPLETED", "last_update": "2020-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01855854", "title": "Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH", "status": "COMPLETED", "last_update": "2019-07-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01993784", "title": "Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.", "status": "UNKNOWN", "last_update": "2013-11-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02011594", "title": "Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma", "status": "WITHDRAWN", "last_update": "2015-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02034968", "title": "Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma", "status": "WITHDRAWN", "last_update": "2015-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02041819", "title": "Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus", "status": "WITHDRAWN", "last_update": "2015-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02123381", "title": "Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2020-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02213289", "title": "PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression", "status": "COMPLETED", "last_update": "2021-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02272699", "title": "Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma", "status": "WITHDRAWN", "last_update": "2021-03-18", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02318901", "title": "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer", "status": "TERMINATED", "last_update": "2019-10-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02591784", "title": "Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer", "status": "COMPLETED", "last_update": "2022-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02636088", "title": "Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal Cancer", "status": "UNKNOWN", "last_update": "2018-09-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02858206", "title": "Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma", "status": "UNKNOWN", "last_update": "2019-07-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03114319", "title": "Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2026-07-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03126708", "title": "Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2018-01-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03185988", "title": "Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System", "status": "UNKNOWN", "last_update": "2019-07-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03200691", "title": "Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2017-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03518554", "title": "A First in Human, Dose Escalation Study of JAB-3068 \uff08SHP2 Inhibitor\uff09 in Adult Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2024-12-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03565003", "title": "A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China", "status": "COMPLETED", "last_update": "2024-09-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03634982", "title": "Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors", "status": "UNKNOWN", "last_update": "2022-09-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03766178", "title": "Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2021-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03817567", "title": "Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2019-01-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03888092", "title": "Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification", "status": "COMPLETED", "last_update": "2023-03-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03940976", "title": "Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)", "status": "UNKNOWN", "last_update": "2019-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03989115", "title": "Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC", "status": "COMPLETED", "last_update": "2023-06-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04045496", "title": "A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04121286", "title": "A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China", "status": "COMPLETED", "last_update": "2025-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04161560", "title": "Cetuximab - IRDye800 Intraoperative Fluorescence Imaging in Esophagectomy of Esophageal Cancer", "status": "UNKNOWN", "last_update": "2019-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04207918", "title": "A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer", "status": "COMPLETED", "last_update": "2024-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04225117", "title": "A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04229459", "title": "Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04464967", "title": "Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers", "status": "WITHDRAWN", "last_update": "2021-05-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04584008", "title": "Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04603287", "title": "A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04695847", "title": "M1231 in Participants With Solid Tumors", "status": "COMPLETED", "last_update": "2023-07-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04868877", "title": "Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04880811", "title": "Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification", "status": "UNKNOWN", "last_update": "2021-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05104567", "title": "A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)", "status": "COMPLETED", "last_update": "2025-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05355168", "title": "Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma", "status": "COMPLETED", "last_update": "2024-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06022276", "title": "Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors", "status": "UNKNOWN", "last_update": "2023-09-01", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06048913", "title": "Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age", "status": "COMPLETED", "last_update": "2025-07-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06585488", "title": "A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification", "status": "TERMINATED", "last_update": "2026-07-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06607185", "title": "A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07191405", "title": "Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07251062", "title": "A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-26", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07312578", "title": "Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy\uff08nCT\uff09 in the Treatment of Esophageal Squamous Cell Carcinoma", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07653451", "title": "Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07697040", "title": "Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "EGFR", "cetuximab", "nimotuzumab" ] }, "TROP2": { "n": 4, "n_observational": 0, "n_active": 4, "n_withdrawn": 0, "trials": [ { "nct": "NCT05969041", "title": "Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors", "status": "RECRUITING", "last_update": "2024-01-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06065371", "title": "Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy", "status": "RECRUITING", "last_update": "2025-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06329869", "title": "Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06715839", "title": "Target-specific immunoPET Imaging of Digestive System Carcinoma", "status": "RECRUITING", "last_update": "2025-12-31", "phase": "NA", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "TROP2", "TACSTD2" ] } }, "by_drug": { "ADEBRELIMAB": { "n": 26, "n_observational": 0, "n_active": 22, "n_withdrawn": 1, "trials": [ { "nct": "NCT03736863", "title": "A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06339619", "title": "Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06452602", "title": "Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.", "status": "RECRUITING", "last_update": "2026-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06474468", "title": "A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer", "status": "RECRUITING", "last_update": "2025-01-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06510660", "title": "Adebrelimab \u00b1Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC", "status": "RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06663059", "title": "Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study", "status": "RECRUITING", "last_update": "2024-10-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06869213", "title": "A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma", "status": "RECRUITING", "last_update": "2025-10-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06885814", "title": "Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07437898", "title": "Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study", "status": "RECRUITING", "last_update": "2026-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07452601", "title": "Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07595770", "title": "Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07638436", "title": "Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07733830", "title": "Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07796113", "title": "Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC", "status": "RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06178211", "title": "Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial", "status": "NOT_YET_RECRUITING", "last_update": "2023-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06198465", "title": "Perioperative Adebrelimab and Chemotherapy in Esophageal and Esophagogastric Junction Carcinoma", "status": "UNKNOWN", "last_update": "2024-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06225921", "title": "Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas", "status": "UNKNOWN", "last_update": "2024-03-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06247956", "title": "Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06420908", "title": "Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)", "status": "WITHDRAWN", "last_update": "2025-08-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06464614", "title": "Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.", "status": "UNKNOWN", "last_update": "2024-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06508229", "title": "Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06599775", "title": "Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06861777", "title": "Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-11", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06861894", "title": "Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07770672", "title": "An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/\u00b9\u2078F-FDG (2-Deoxy-2-[\u00b9\u2078F]Fluoro-D-glucose) Dual Imaging", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07780721", "title": "Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AFATINIB": { "n": 12, "n_observational": 0, "n_active": 3, "n_withdrawn": 1, "trials": [ { "nct": "NCT06753747", "title": "A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-12-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01522768", "title": "Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer", "status": "COMPLETED", "last_update": "2023-11-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02274012", "title": "Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment", "status": "WITHDRAWN", "last_update": "2017-03-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02353936", "title": "A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus", "status": "UNKNOWN", "last_update": "2019-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03486509", "title": "Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2018-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03940976", "title": "Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)", "status": "UNKNOWN", "last_update": "2019-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04839471", "title": "BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)", "status": "COMPLETED", "last_update": "2024-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04880811", "title": "Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification", "status": "UNKNOWN", "last_update": "2021-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05865132", "title": "Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction", "status": "UNKNOWN", "last_update": "2023-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05927844", "title": "XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2023-07-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07653451", "title": "Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] }, "AFATINIB DIMALEATE": { "n": 12, "n_observational": 0, "n_active": 3, "n_withdrawn": 1, "trials": [ { "nct": "NCT06753747", "title": "A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-12-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01522768", "title": "Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer", "status": "COMPLETED", "last_update": "2023-11-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02274012", "title": "Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment", "status": "WITHDRAWN", "last_update": "2017-03-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02353936", "title": "A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus", "status": "UNKNOWN", "last_update": "2019-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03486509", "title": "Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2018-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03940976", "title": "Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)", "status": "UNKNOWN", "last_update": "2019-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04839471", "title": "BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)", "status": "COMPLETED", "last_update": "2024-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04880811", "title": "Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification", "status": "UNKNOWN", "last_update": "2021-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05865132", "title": "Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction", "status": "UNKNOWN", "last_update": "2023-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05927844", "title": "XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2023-07-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07653451", "title": "Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] }, "AMIVANTAMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT04945733", "title": "A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer", "status": "TERMINATED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ATEZOLIZUMAB": { "n": 30, "n_observational": 0, "n_active": 12, "n_withdrawn": 2, "trials": [ { "nct": "NCT05944237", "title": "HTL0039732 in Participants With Advanced Solid Tumours", "status": "RECRUITING", "last_update": "2025-06-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06422403", "title": "A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers", "status": "RECRUITING", "last_update": "2025-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06819566", "title": "Prophylactic Endoscopic Variceal Ligation in Patients With High-risk Esophageal Varices Receiving Atezo/Bev for HCC", "status": "RECRUITING", "last_update": "2025-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06961526", "title": "Esophageal Varices Prophylaxis in Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab", "status": "RECRUITING", "last_update": "2025-05-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07385001", "title": "A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC", "status": "RECRUITING", "last_update": "2026-02-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02876510", "title": "ACTolog in Patients With Solid Cancers", "status": "COMPLETED", "last_update": "2025-02-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03087864", "title": "PDL-1 Targeting in Resectable Oesophageal Cancer", "status": "COMPLETED", "last_update": "2020-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03212469", "title": "A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer", "status": "COMPLETED", "last_update": "2025-05-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03281369", "title": "A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)", "status": "TERMINATED", "last_update": "2026-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03386721", "title": "Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2023-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03399071", "title": "Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer", "status": "UNKNOWN", "last_update": "2023-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03421288", "title": "Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03448835", "title": "Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544723", "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.", "status": "UNKNOWN", "last_update": "2020-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03818997", "title": "Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer", "status": "WITHDRAWN", "last_update": "2020-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03829501", "title": "A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies", "status": "TERMINATED", "last_update": "2025-04-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03982173", "title": "Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors", "status": "WITHDRAWN", "last_update": "2023-01-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04116320", "title": "Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04166721", "title": "WaKING: Wnt and checKpoint INhibition in Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04540211", "title": "A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma", "status": "COMPLETED", "last_update": "2026-08-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04543617", "title": "A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04564482", "title": "PD-L1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer", "status": "UNKNOWN", "last_update": "2024-03-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04604132", "title": "Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma", "status": "TERMINATED", "last_update": "2024-04-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04713891", "title": "A Study of KF-0210 in Advanced Solid Tumors Patients", "status": "COMPLETED", "last_update": "2024-09-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05007613", "title": "Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2025-01-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05411133", "title": "Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients", "status": "COMPLETED", "last_update": "2026-03-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05581004", "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07770100", "title": "Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AVELUMAB": { "n": 9, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT05267626", "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02625610", "title": "Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)", "status": "COMPLETED", "last_update": "2022-06-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03399071", "title": "Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer", "status": "UNKNOWN", "last_update": "2023-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03475953", "title": "A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors", "status": "UNKNOWN", "last_update": "2023-03-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03490292", "title": "Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer", "status": "COMPLETED", "last_update": "2024-07-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03783936", "title": "Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas", "status": "COMPLETED", "last_update": "2023-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03800953", "title": "The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2021-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03966118", "title": "Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma", "status": "UNKNOWN", "last_update": "2019-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "BALSTILIMAB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06251973", "title": "A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "BINTRAFUSP ALFA": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT04481256", "title": "TGF-\u03b2 And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY", "status": "RECRUITING", "last_update": "2024-07-26", "phase": "NA", "study_type": "INTERVENTIONAL" } ] }, "BUDIGALIMAB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT05005403", "title": "Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan", "status": "RECRUITING", "last_update": "2026-06-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "CADONILIMAB": { "n": 9, "n_observational": 0, "n_active": 6, "n_withdrawn": 0, "trials": [ { "nct": "NCT06232083", "title": "A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR)", "status": "RECRUITING", "last_update": "2025-07-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06356688", "title": "A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05522894", "title": "AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC", "status": "UNKNOWN", "last_update": "2022-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05732662", "title": "SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC", "status": "NOT_YET_RECRUITING", "last_update": "2023-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05974059", "title": "Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer", "status": "UNKNOWN", "last_update": "2023-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05990231", "title": "Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy", "status": "UNKNOWN", "last_update": "2023-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06143748", "title": "Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06426797", "title": "Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-05-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06681285", "title": "Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)", "status": "NOT_YET_RECRUITING", "last_update": "2024-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CAMRELIZUMAB": { "n": 64, "n_observational": 4, "n_active": 24, "n_withdrawn": 0, "trials": [ { "nct": "NCT03736863", "title": "A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05182944", "title": "A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC", "status": "RECRUITING", "last_update": "2022-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05507411", "title": "Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC", "status": "RECRUITING", "last_update": "2022-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05624099", "title": "Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.", "status": "RECRUITING", "last_update": "2023-10-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05738434", "title": "Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC", "status": "RECRUITING", "last_update": "2024-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05937438", "title": "Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma", "status": "RECRUITING", "last_update": "2025-01-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06084897", "title": "Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy", "status": "RECRUITING", "last_update": "2024-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06086457", "title": "PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer", "status": "RECRUITING", "last_update": "2024-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06339060", "title": "An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).", "status": "RECRUITING", "last_update": "2024-07-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06354530", "title": "A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-04-09", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06869226", "title": "A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer", "status": "RECRUITING", "last_update": "2025-10-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07162506", "title": "DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI", "status": "RECRUITING", "last_update": "2026-05-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07530094", "title": "Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03099382", "title": "Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer", "status": "COMPLETED", "last_update": "2024-01-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03187314", "title": "Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer", "status": "COMPLETED", "last_update": "2020-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03222440", "title": "Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC", "status": "COMPLETED", "last_update": "2019-12-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03603756", "title": "SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer", "status": "UNKNOWN", "last_update": "2020-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03671265", "title": "Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC", "status": "UNKNOWN", "last_update": "2019-01-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03691090", "title": "Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer", "status": "COMPLETED", "last_update": "2022-12-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03766178", "title": "Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2021-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03817658", "title": "A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC", "status": "UNKNOWN", "last_update": "2019-01-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04225364", "title": "Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2021-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04286958", "title": "A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC", "status": "UNKNOWN", "last_update": "2021-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04390945", "title": "Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer", "status": "UNKNOWN", "last_update": "2022-02-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04404491", "title": "Clinical Control Study of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer Recurrence", "status": "UNKNOWN", "last_update": "2020-05-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04426955", "title": "Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer", "status": "UNKNOWN", "last_update": "2021-09-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04471480", "title": "TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer", "status": "UNKNOWN", "last_update": "2020-07-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04506138", "title": "Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2021-12-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04510818", "title": "Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2)", "status": "UNKNOWN", "last_update": "2020-08-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04512417", "title": "A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer", "status": "UNKNOWN", "last_update": "2020-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04654403", "title": "Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer", "status": "UNKNOWN", "last_update": "2021-08-23", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04767295", "title": "A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)", "status": "UNKNOWN", "last_update": "2021-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04797507", "title": "SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer", "status": "UNKNOWN", "last_update": "2021-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04866381", "title": "An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody", "status": "UNKNOWN", "last_update": "2021-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04984018", "title": "Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade", "status": "UNKNOWN", "last_update": "2021-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05049681", "title": "Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell", "status": "UNKNOWN", "last_update": "2021-09-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05050760", "title": "DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer", "status": "UNKNOWN", "last_update": "2023-01-31", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05170542", "title": "The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.", "status": "UNKNOWN", "last_update": "2021-12-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05174156", "title": "Study on the Biomarker of First-line Immunotherapy Combined With Chemotherapy in Advanced Esophageal Cancer", "status": "UNKNOWN", "last_update": "2022-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05176002", "title": "Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05183958", "title": "A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer", "status": "UNKNOWN", "last_update": "2022-01-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05184946", "title": "Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction Adenocarcinoma", "status": "UNKNOWN", "last_update": "2022-01-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05322499", "title": "Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer", "status": "UNKNOWN", "last_update": "2022-04-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05355168", "title": "Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma", "status": "COMPLETED", "last_update": "2024-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05476380", "title": "Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2022-07-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05637268", "title": "Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2022-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05650216", "title": "Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC\uff08NICE-RT\uff09", "status": "UNKNOWN", "last_update": "2022-12-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05777707", "title": "Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05821452", "title": "Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma", "status": "UNKNOWN", "last_update": "2023-04-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06010212", "title": "Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2023-08-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06048926", "title": "Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma", "status": "ENROLLING_BY_INVITATION", "last_update": "2023-09-21", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06055166", "title": "A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors", "status": "UNKNOWN", "last_update": "2023-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06231680", "title": "Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)", "status": "UNKNOWN", "last_update": "2024-03-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06654297", "title": "Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06745193", "title": "A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07015489", "title": "Concurrent Radiotherapy Following Induction Chemoimmunotherapy for Locally Advanced Esophageal Cancer", "status": "COMPLETED", "last_update": "2025-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07016737", "title": "Immunochemotherapy \u00b1 Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-06-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07067450", "title": "Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-16", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07191977", "title": "Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07236320", "title": "Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC", "status": "COMPLETED", "last_update": "2025-11-19", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07251062", "title": "A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-26", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07312578", "title": "Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy\uff08nCT\uff09 in the Treatment of Esophageal Squamous Cell Carcinoma", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07505186", "title": "Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07653451", "title": "Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] }, "CEMIPLIMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT05864144", "title": "A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CETUXIMAB": { "n": 40, "n_observational": 2, "n_active": 4, "n_withdrawn": 2, "trials": [ { "nct": "NCT05745857", "title": "Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05910827", "title": "A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers", "status": "RECRUITING", "last_update": "2026-05-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00096031", "title": "S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2018-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00109850", "title": "S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer", "status": "TERMINATED", "last_update": "2015-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00130689", "title": "Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer", "status": "COMPLETED", "last_update": "2015-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00165490", "title": "Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer", "status": "COMPLETED", "last_update": "2014-11-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00183898", "title": "Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00319735", "title": "Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas", "status": "COMPLETED", "last_update": "2016-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00381706", "title": "Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2021-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00397384", "title": "Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer", "status": "COMPLETED", "last_update": "2015-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00397904", "title": "Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin", "status": "COMPLETED", "last_update": "2015-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00425425", "title": "Cetuximab, Oxaliplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Esophageal Cancer", "status": "UNKNOWN", "last_update": "2014-05-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00439608", "title": "Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer", "status": "COMPLETED", "last_update": "2020-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00445861", "title": "Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery", "status": "COMPLETED", "last_update": "2012-06-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00509561", "title": "Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer", "status": "UNKNOWN", "last_update": "2012-12-18", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00544362", "title": "Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery", "status": "COMPLETED", "last_update": "2016-05-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00551759", "title": "Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer", "status": "TERMINATED", "last_update": "2023-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00578201", "title": "FOLFOX-Cetuximab-radiotherapy for the Treatment of Esophageal Cancer", "status": "COMPLETED", "last_update": "2011-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00636298", "title": "Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy", "status": "WITHDRAWN", "last_update": "2013-11-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00655876", "title": "Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer", "status": "COMPLETED", "last_update": "2022-06-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00678535", "title": "Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer", "status": "COMPLETED", "last_update": "2014-07-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00733889", "title": "A Study to Evaluate the Combination of Cetuximab and Chemotherapy as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy Plus Cetuximab in Locoregional Esophageal Carcinoma", "status": "COMPLETED", "last_update": "2013-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00735345", "title": "Chemotherapy Induction and Chemoradiotherapy in Patients With Esophageal Carcinoma", "status": "TERMINATED", "last_update": "2015-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00757549", "title": "3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx", "status": "COMPLETED", "last_update": "2017-10-31", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00815308", "title": "Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2011-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00827671", "title": "Study of Combination of Cetuximab and Radiotherapy Added to the Standard Treatment for Oesophageal Adenocarcinoma", "status": "TERMINATED", "last_update": "2018-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01034189", "title": "Cetuximab/Paclitaxel/Cisplatin Concurrent Chemoradiotherapy Followed by Esophagectomy for Loco-regional Esophageal Cancer", "status": "UNKNOWN", "last_update": "2009-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01107639", "title": "Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery", "status": "COMPLETED", "last_update": "2020-10-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01787006", "title": "Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer", "status": "COMPLETED", "last_update": "2020-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02123381", "title": "Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2020-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02318901", "title": "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer", "status": "TERMINATED", "last_update": "2019-10-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02636088", "title": "Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal Cancer", "status": "UNKNOWN", "last_update": "2018-09-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03126708", "title": "Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2018-01-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04161560", "title": "Cetuximab - IRDye800 Intraoperative Fluorescence Imaging in Esophagectomy of Esophageal Cancer", "status": "UNKNOWN", "last_update": "2019-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04229459", "title": "Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04464967", "title": "Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers", "status": "WITHDRAWN", "last_update": "2021-05-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05104567", "title": "A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)", "status": "COMPLETED", "last_update": "2025-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06585488", "title": "A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification", "status": "TERMINATED", "last_update": "2026-07-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06607185", "title": "A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "CONTUSUGENE LADENOVEC": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03544723", "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.", "status": "UNKNOWN", "last_update": "2020-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DACOMITINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01608022", "title": "A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus", "status": "COMPLETED", "last_update": "2016-09-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DEPATUXIZUMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02213289", "title": "PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression", "status": "COMPLETED", "last_update": "2021-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DOSTARLIMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT04779151", "title": "Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab", "status": "TERMINATED", "last_update": "2025-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DURVALUMAB": { "n": 34, "n_observational": 1, "n_active": 18, "n_withdrawn": 1, "trials": [ { "nct": "NCT03539822", "title": "Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04900818", "title": "Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-03-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05187338", "title": "Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06290505", "title": "A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06824363", "title": "ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07222657", "title": "Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07700420", "title": "Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01938612", "title": "A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours", "status": "COMPLETED", "last_update": "2021-03-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02520453", "title": "Adjuvant Durvalumab for Esophageal Cancer", "status": "UNKNOWN", "last_update": "2019-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02639065", "title": "A Study of Durvalumab (MEDI4736) in Esophageal Cancer", "status": "COMPLETED", "last_update": "2023-09-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02658214", "title": "Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2020-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02678182", "title": "Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02735239", "title": "Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer", "status": "COMPLETED", "last_update": "2024-03-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02962063", "title": "Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03174275", "title": "Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03212469", "title": "A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer", "status": "COMPLETED", "last_update": "2025-05-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03292250", "title": "Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]", "status": "COMPLETED", "last_update": "2022-03-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03377400", "title": "Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer", "status": "UNKNOWN", "last_update": "2020-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544723", "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.", "status": "UNKNOWN", "last_update": "2020-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03653052", "title": "Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03777813", "title": "Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer", "status": "COMPLETED", "last_update": "2025-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03959293", "title": "Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma", "status": "UNKNOWN", "last_update": "2024-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03982173", "title": "Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors", "status": "WITHDRAWN", "last_update": "2023-01-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03983954", "title": "Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04054518", "title": "Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2019-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04159974", "title": "RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus", "status": "UNKNOWN", "last_update": "2024-05-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379596", "title": "Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04550260", "title": "Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04568200", "title": "Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2024-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04851132", "title": "Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2021-06-22", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05667298", "title": "Organ-Preserving Endoscopic Resection & Adjuvant RADIO-immuno-chemotherapy for Esophageal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05713838", "title": "Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07565857", "title": "Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07625930", "title": "RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ENVAFOLIMAB": { "n": 3, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT07266493", "title": "Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05552651", "title": "Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2022-09-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05828381", "title": "Envafolimab Combined With Abraxane and Cisplatinas as Neoadjuvant Treatment for Resectable Esophageal Cancer", "status": "UNKNOWN", "last_update": "2023-04-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "EPRENETAPOPT": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02999893", "title": "A Study of APR-246 in Oesophageal Cancer", "status": "TERMINATED", "last_update": "2021-12-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ERLOTINIB": { "n": 12, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00030498", "title": "Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction", "status": "COMPLETED", "last_update": "2013-01-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00032123", "title": "Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2013-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00045526", "title": "Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer", "status": "COMPLETED", "last_update": "2013-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00393068", "title": "Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer", "status": "COMPLETED", "last_update": "2022-03-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00397384", "title": "Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer", "status": "COMPLETED", "last_update": "2015-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00442507", "title": "Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction", "status": "TERMINATED", "last_update": "2015-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00524121", "title": "Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal Cancer", "status": "COMPLETED", "last_update": "2016-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00539617", "title": "Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery", "status": "TERMINATED", "last_update": "2020-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00566800", "title": "Erlotinib in Treating Patients With Barrett Esophagus", "status": "UNKNOWN", "last_update": "2013-09-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00591123", "title": "Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia", "status": "COMPLETED", "last_update": "2021-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00686114", "title": "Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer", "status": "UNKNOWN", "last_update": "2014-04-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01561014", "title": "Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction", "status": "COMPLETED", "last_update": "2018-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "GEFITINIB": { "n": 10, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00093652", "title": "Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer", "status": "TERMINATED", "last_update": "2015-10-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00100945", "title": "Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer", "status": "COMPLETED", "last_update": "2016-12-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00215995", "title": "Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas", "status": "COMPLETED", "last_update": "2012-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00258297", "title": "Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery", "status": "TERMINATED", "last_update": "2013-10-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00258323", "title": "Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2015-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00268346", "title": "Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2016-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00290719", "title": "Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery", "status": "TERMINATED", "last_update": "2014-05-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00493025", "title": "Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery", "status": "TERMINATED", "last_update": "2018-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01243398", "title": "Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy", "status": "COMPLETED", "last_update": "2012-11-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01291823", "title": "Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal Cancer", "status": "UNKNOWN", "last_update": "2011-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ICOTINIB": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01855854", "title": "Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH", "status": "COMPLETED", "last_update": "2019-07-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01973725", "title": "Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy", "status": "COMPLETED", "last_update": "2023-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02375581", "title": "Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer", "status": "UNKNOWN", "last_update": "2016-03-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "KN-026": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT05427383", "title": "KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy", "status": "RECRUITING", "last_update": "2023-12-19", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] }, "LAPATINIB": { "n": 9, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00239200", "title": "Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus", "status": "TERMINATED", "last_update": "2008-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00313599", "title": "Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2014-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00447226", "title": "Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists", "status": "TERMINATED", "last_update": "2012-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00450203", "title": "Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer", "status": "UNKNOWN", "last_update": "2016-12-01", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00526669", "title": "Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib", "status": "COMPLETED", "last_update": "2016-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00680901", "title": "LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib", "status": "COMPLETED", "last_update": "2025-08-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01145404", "title": "Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer", "status": "TERMINATED", "last_update": "2014-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01705340", "title": "Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery", "status": "TERMINATED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "LAPATINIB DITOSYLATE": { "n": 9, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00239200", "title": "Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus", "status": "TERMINATED", "last_update": "2008-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00313599", "title": "Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2014-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00447226", "title": "Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists", "status": "TERMINATED", "last_update": "2012-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00450203", "title": "Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer", "status": "UNKNOWN", "last_update": "2016-12-01", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00526669", "title": "Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib", "status": "COMPLETED", "last_update": "2016-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00680901", "title": "LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib", "status": "COMPLETED", "last_update": "2025-08-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01145404", "title": "Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer", "status": "TERMINATED", "last_update": "2014-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01705340", "title": "Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery", "status": "TERMINATED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "LOMVASTOMIG": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03708328", "title": "A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2025-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04785820", "title": "A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus", "status": "COMPLETED", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "MARGETUXIMAB": { "n": 2, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02689284", "title": "Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2025-03-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "MATUZUMAB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00113581", "title": "Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer", "status": "COMPLETED", "last_update": "2014-02-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00215644", "title": "Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer", "status": "COMPLETED", "last_update": "2018-11-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "MM-111": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01774851", "title": "A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach", "status": "TERMINATED", "last_update": "2017-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "NAZARTINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03114319", "title": "Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2026-07-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "NERATINIB": { "n": 3, "n_observational": 0, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT05274048", "title": "Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients", "status": "RECRUITING", "last_update": "2025-10-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06374888", "title": "Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases", "status": "NOT_YET_RECRUITING", "last_update": "2024-04-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "NIMOTUZUMAB": { "n": 29, "n_observational": 0, "n_active": 8, "n_withdrawn": 4, "trials": [ { "nct": "NCT04821778", "title": "Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04821843", "title": "Neoadjuvant Treatment Modalities in Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06410651", "title": "Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06429839", "title": "Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients", "status": "RECRUITING", "last_update": "2024-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06718205", "title": "Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06988956", "title": "Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-05-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07457528", "title": "Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC", "status": "RECRUITING", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00950417", "title": "Nimotuzumab in Combination With Chemoradiation for Esophageal Cancer", "status": "COMPLETED", "last_update": "2015-08-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01232374", "title": "Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2015-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01249352", "title": "A Study of Chemoradiation Associated with Nimotuzumab As the Treatment of Locally Advanced Esophageal Cancer", "status": "COMPLETED", "last_update": "2025-03-31", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01336049", "title": "Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer", "status": "UNKNOWN", "last_update": "2011-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01402180", "title": "Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy", "status": "UNKNOWN", "last_update": "2011-07-26", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01463605", "title": "Nimotuzumab Combined With Radiotherapy for Older Patients With Esophageal Cancer: a Single, Non-control Clinical Trial", "status": "COMPLETED", "last_update": "2021-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01486992", "title": "mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus", "status": "UNKNOWN", "last_update": "2012-01-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01688700", "title": "Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2012-09-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01993784", "title": "Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.", "status": "UNKNOWN", "last_update": "2013-11-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02011594", "title": "Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma", "status": "WITHDRAWN", "last_update": "2015-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02034968", "title": "Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma", "status": "WITHDRAWN", "last_update": "2015-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02041819", "title": "Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus", "status": "WITHDRAWN", "last_update": "2015-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02272699", "title": "Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma", "status": "WITHDRAWN", "last_update": "2021-03-18", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02591784", "title": "Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer", "status": "COMPLETED", "last_update": "2022-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02858206", "title": "Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma", "status": "UNKNOWN", "last_update": "2019-07-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03200691", "title": "Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2017-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03766178", "title": "Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2021-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04207918", "title": "A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer", "status": "COMPLETED", "last_update": "2024-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05355168", "title": "Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma", "status": "COMPLETED", "last_update": "2024-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06022276", "title": "Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors", "status": "UNKNOWN", "last_update": "2023-09-01", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06048913", "title": "Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age", "status": "COMPLETED", "last_update": "2025-07-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07312578", "title": "Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy\uff08nCT\uff09 in the Treatment of Esophageal Squamous Cell Carcinoma", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "NIVOLUMAB": { "n": 66, "n_observational": 10, "n_active": 34, "n_withdrawn": 2, "trials": [ { "nct": "NCT04114136", "title": "Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies", "status": "RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04900818", "title": "Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-03-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05187182", "title": "CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-04-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05267626", "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05332002", "title": "sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)", "status": "RECRUITING", "last_update": "2026-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05677490", "title": "mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06022861", "title": "A Study to Compare the Efficacy and Safety of LY01015 and Opdivo\u00ae Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-09-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06047379", "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06084897", "title": "Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy", "status": "RECRUITING", "last_update": "2024-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06203600", "title": "Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06265285", "title": "Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program", "status": "RECRUITING", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06422403", "title": "A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers", "status": "RECRUITING", "last_update": "2025-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07000253", "title": "Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07152678", "title": "Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07221149", "title": "A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07223424", "title": "Patient Preference for Subcutaneous vs. Intravenous Immune Therapy", "status": "RECRUITING", "last_update": "2026-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07334119", "title": "Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07392892", "title": "Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07431281", "title": "Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07432295", "title": "Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)", "status": "RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07518043", "title": "A Study of HLX18 vs. OPDIVO\u00ae in Multiple Resected Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02213289", "title": "PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression", "status": "COMPLETED", "last_update": "2021-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02569242", "title": "Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer", "status": "COMPLETED", "last_update": "2022-07-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02743494", "title": "An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2025-11-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02834013", "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02872116", "title": "Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer", "status": "COMPLETED", "last_update": "2025-08-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02946671", "title": "Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients", "status": "COMPLETED", "last_update": "2020-03-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03044613", "title": "Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03126110", "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies", "status": "COMPLETED", "last_update": "2025-08-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03143153", "title": "A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin", "status": "COMPLETED", "last_update": "2026-02-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03220009", "title": "Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma", "status": "WITHDRAWN", "last_update": "2018-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03241173", "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies", "status": "COMPLETED", "last_update": "2022-09-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03278626", "title": "Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2022-03-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03409848", "title": "Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma", "status": "COMPLETED", "last_update": "2022-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03416244", "title": "A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer", "status": "COMPLETED", "last_update": "2022-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03505320", "title": "A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544723", "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.", "status": "UNKNOWN", "last_update": "2020-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544736", "title": "Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2023-03-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03764553", "title": "Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03914443", "title": "A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma", "status": "COMPLETED", "last_update": "2025-05-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03987815", "title": "Neoadjuvant Nivolumab for Operable Esophageal Carcinoma", "status": "UNKNOWN", "last_update": "2020-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03993353", "title": "Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2026-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03995017", "title": "Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma", "status": "UNKNOWN", "last_update": "2023-02-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04044859", "title": "ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04062656", "title": "Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG", "status": "UNKNOWN", "last_update": "2024-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04229459", "title": "Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04503967", "title": "Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer", "status": "UNKNOWN", "last_update": "2020-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04594811", "title": "NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma", "status": "TERMINATED", "last_update": "2024-08-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04704154", "title": "A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors", "status": "COMPLETED", "last_update": "2025-04-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04757363", "title": "A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04785820", "title": "A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus", "status": "COMPLETED", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04879368", "title": "RegoNivo vs Standard of Care Chemotherapy in AGOC", "status": "COMPLETED", "last_update": "2026-06-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04925284", "title": "Study of XB002 in Subjects With Solid Tumors (JEWEL-101)", "status": "COMPLETED", "last_update": "2025-04-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04984733", "title": "Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer", "status": "COMPLETED", "last_update": "2026-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05053295", "title": "Investigator-initiated Pilot Study to Investigate the Efficacy and Safety of Immuncell-LC in Combination With Nivolumab (Opdivo) in Subjects With Advanced or Recurrent Gastric Cancer", "status": "UNKNOWN", "last_update": "2021-09-22", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05213312", "title": "Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC", "status": "UNKNOWN", "last_update": "2022-06-15", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05476796", "title": "Oxaliplatin \u00b1 Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05480384", "title": "Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05491616", "title": "Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05568095", "title": "A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body", "status": "COMPLETED", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05898828", "title": "Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer", "status": "WITHDRAWN", "last_update": "2024-08-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06034860", "title": "Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types", "status": "TERMINATED", "last_update": "2024-11-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06728657", "title": "Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma", "status": "SUSPENDED", "last_update": "2025-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07770100", "title": "Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "OSIMERTINIB": { "n": 3, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03989115", "title": "Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC", "status": "COMPLETED", "last_update": "2023-06-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04868877", "title": "Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PALBOCICLIB": { "n": 6, "n_observational": 0, "n_active": 5, "n_withdrawn": 0, "trials": [ { "nct": "NCT06753747", "title": "A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-12-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238922", "title": "Study of INCB123667 in Subjects With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05865132", "title": "Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction", "status": "UNKNOWN", "last_update": "2023-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06654297", "title": "Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07191977", "title": "Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PANITUMUMAB": { "n": 13, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00004879", "title": "Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2013-01-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00101907", "title": "Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer", "status": "TERMINATED", "last_update": "2014-03-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00578071", "title": "Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer", "status": "COMPLETED", "last_update": "2015-07-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00757172", "title": "Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction", "status": "COMPLETED", "last_update": "2016-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00824785", "title": "REAL3 Trial of Efficacy of EOX With/Without Panitumumab in Previously Untreated Adv OG Cancer", "status": "TERMINATED", "last_update": "2012-12-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00836277", "title": "Phase II Study of Irinotecan and Panitumumab", "status": "COMPLETED", "last_update": "2016-11-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01077999", "title": "Chemoradiation and Panitumumab for Esophageal Cancer", "status": "COMPLETED", "last_update": "2021-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01128387", "title": "Trial of Panitumumab/Cisplatin/Fluorouracil Combined With Radiation in Esophageal Cancer", "status": "TERMINATED", "last_update": "2019-12-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01262183", "title": "Radio-chemotherapy With or Without Panitumumab (Vectibix\u00ae) in Irresectable Squamous Cell Carcinoma or Adenocarcinoma of the Oesophagus", "status": "TERMINATED", "last_update": "2012-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01307956", "title": "Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer", "status": "TERMINATED", "last_update": "2023-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01443065", "title": "MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma", "status": "COMPLETED", "last_update": "2020-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01627379", "title": "Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer", "status": "TERMINATED", "last_update": "2018-03-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01716546", "title": "Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer", "status": "TERMINATED", "last_update": "2015-10-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PEMBROLIZUMAB": { "n": 115, "n_observational": 2, "n_active": 54, "n_withdrawn": 3, "trials": [ { "nct": "NCT03526835", "title": "A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03556228", "title": "VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma", "status": "RECRUITING", "last_update": "2025-12-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04114136", "title": "Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies", "status": "RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04389632", "title": "A Study of Sigvotatug Vedotin in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04592211", "title": "Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer", "status": "RECRUITING", "last_update": "2025-07-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04807673", "title": "Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)", "status": "RECRUITING", "last_update": "2022-06-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05086692", "title": "A Beta-only IL-2 ImmunoTherapY Study", "status": "RECRUITING", "last_update": "2025-07-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05144698", "title": "RAPA-201 Therapy of Solid Tumors", "status": "RECRUITING", "last_update": "2025-05-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05187182", "title": "CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-04-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05187338", "title": "Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05208762", "title": "A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05319730", "title": "A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05954312", "title": "A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06006650", "title": "Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell", "status": "RECRUITING", "last_update": "2023-08-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06047379", "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06084897", "title": "Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy", "status": "RECRUITING", "last_update": "2024-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06123338", "title": "A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06304350", "title": "Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06422403", "title": "A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers", "status": "RECRUITING", "last_update": "2025-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06445972", "title": "Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06469944", "title": "Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06532799", "title": "TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer", "status": "RECRUITING", "last_update": "2024-11-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06545331", "title": "Study of XB010 in Subjects With Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06780111", "title": "Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06907602", "title": "Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-04-02", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07000253", "title": "Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07223424", "title": "Patient Preference for Subcutaneous vs. Intravenous Immune Therapy", "status": "RECRUITING", "last_update": "2026-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07227168", "title": "A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07403136", "title": "Becotatug Vedotin \u00b1 Anti-PD-1 in Pretreated Advanced ESCC", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07405151", "title": "A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07410676", "title": "EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 \u00b1 Pembrolizumab in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-02-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07455019", "title": "A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07730021", "title": "A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07749586", "title": "A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02013154", "title": "A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab", "status": "COMPLETED", "last_update": "2025-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02318901", "title": "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer", "status": "TERMINATED", "last_update": "2019-10-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02559687", "title": "Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)", "status": "COMPLETED", "last_update": "2022-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02564263", "title": "Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)", "status": "COMPLETED", "last_update": "2023-03-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02635672", "title": "Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer", "status": "COMPLETED", "last_update": "2024-11-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02642809", "title": "Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers", "status": "COMPLETED", "last_update": "2026-03-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02689284", "title": "Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2025-03-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02757391", "title": "CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors", "status": "TERMINATED", "last_update": "2020-10-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02830594", "title": "Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2024-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02844075", "title": "Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29)", "status": "COMPLETED", "last_update": "2024-11-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02954536", "title": "Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer", "status": "COMPLETED", "last_update": "2023-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02971956", "title": "Pembrolizumab in Refractory Advanced Esophageal Cancer", "status": "COMPLETED", "last_update": "2023-09-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03064490", "title": "Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)", "status": "COMPLETED", "last_update": "2025-04-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03122548", "title": "Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers", "status": "TERMINATED", "last_update": "2019-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03189719", "title": "First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)", "status": "COMPLETED", "last_update": "2024-10-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03196232", "title": "Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer", "status": "COMPLETED", "last_update": "2024-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03233724", "title": "Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas", "status": "TERMINATED", "last_update": "2023-05-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03236935", "title": "Phase Ib of L-NMMA and Pembrolizumab", "status": "COMPLETED", "last_update": "2026-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03277352", "title": "INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies", "status": "TERMINATED", "last_update": "2021-07-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03322267", "title": "Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence", "status": "COMPLETED", "last_update": "2026-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03329950", "title": "A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies", "status": "COMPLETED", "last_update": "2024-03-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03342937", "title": "KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer", "status": "COMPLETED", "last_update": "2024-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03395847", "title": "Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma", "status": "COMPLETED", "last_update": "2023-11-18", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03488667", "title": "Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2023-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03505320", "title": "A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544723", "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.", "status": "UNKNOWN", "last_update": "2020-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03592407", "title": "Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer", "status": "WITHDRAWN", "last_update": "2022-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03621982", "title": "Study of ADCT-301 in Patients With Selected Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-06-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03697824", "title": "Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a", "status": "WITHDRAWN", "last_update": "2019-10-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03709706", "title": "Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab", "status": "TERMINATED", "last_update": "2024-02-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03792347", "title": "Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus", "status": "COMPLETED", "last_update": "2023-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03809624", "title": "Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer", "status": "TERMINATED", "last_update": "2024-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03881111", "title": "First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study", "status": "WITHDRAWN", "last_update": "2020-02-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03933449", "title": "Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study", "status": "COMPLETED", "last_update": "2023-03-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03993353", "title": "Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2026-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04032704", "title": "A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04041310", "title": "Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04044859", "title": "ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04060342", "title": "GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma", "status": "TERMINATED", "last_update": "2022-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04116320", "title": "Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04140526", "title": "Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04187872", "title": "LITT and Pembrolizumab in Recurrent Brain Metastasis", "status": "TERMINATED", "last_update": "2023-12-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04210115", "title": "Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)", "status": "COMPLETED", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04225117", "title": "A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04244552", "title": "A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies", "status": "TERMINATED", "last_update": "2023-12-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379596", "title": "Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04389177", "title": "Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)", "status": "UNKNOWN", "last_update": "2023-04-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04430738", "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04435197", "title": "Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2024-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04508140", "title": "Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis", "status": "TERMINATED", "last_update": "2024-11-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04510285", "title": "A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection", "status": "TERMINATED", "last_update": "2023-02-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04913337", "title": "Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies", "status": "UNKNOWN", "last_update": "2024-10-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04929392", "title": "Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04949256", "title": "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).", "status": "TERMINATED", "last_update": "2026-08-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05007106", "title": "MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)", "status": "COMPLETED", "last_update": "2025-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05070247", "title": "A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2026-01-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05104567", "title": "A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)", "status": "COMPLETED", "last_update": "2025-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05170256", "title": "Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients", "status": "UNKNOWN", "last_update": "2022-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05215574", "title": "Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05281003", "title": "Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)", "status": "UNKNOWN", "last_update": "2023-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05302011", "title": "Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2023-10-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05311618", "title": "Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors", "status": "UNKNOWN", "last_update": "2024-04-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05342636", "title": "A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)", "status": "COMPLETED", "last_update": "2025-12-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05386056", "title": "Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2022-11-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05438420", "title": "Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05541445", "title": "Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC", "status": "UNKNOWN", "last_update": "2022-09-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05544929", "title": "A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05572684", "title": "A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2026-08-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05581004", "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05708950", "title": "A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)", "status": "COMPLETED", "last_update": "2026-06-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05714553", "title": "NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours", "status": "TERMINATED", "last_update": "2026-07-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05945823", "title": "Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06116136", "title": "A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06607185", "title": "A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06682806", "title": "A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation", "status": "TERMINATED", "last_update": "2026-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06728657", "title": "Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma", "status": "SUSPENDED", "last_update": "2025-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07067450", "title": "Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-16", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07218003", "title": "A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07770100", "title": "Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07807345", "title": "Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "PENPULIMAB": { "n": 3, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06586242", "title": "Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy", "status": "RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05265962", "title": "Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade", "status": "UNKNOWN", "last_update": "2022-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05561699", "title": "Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell Cancer", "status": "UNKNOWN", "last_update": "2022-09-30", "phase": "NA", "study_type": "INTERVENTIONAL" } ] }, "PERTUZUMAB": { "n": 6, "n_observational": 0, "n_active": 4, "n_withdrawn": 0, "trials": [ { "nct": "NCT05188313", "title": "TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer", "status": "RECRUITING", "last_update": "2022-06-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06414733", "title": "HER-2 B Cell Peptide Vaccine", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02120911", "title": "Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma", "status": "COMPLETED", "last_update": "2020-07-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02205047", "title": "Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma", "status": "COMPLETED", "last_update": "2025-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "POZIOTINIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03292250", "title": "Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]", "status": "COMPLETED", "last_update": "2022-03-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03770988", "title": "A Trial to Evaluate the Efficacy of Poziotinib, Pan HER Inhibitor in Recurrent/Metastatic Esophageal Cancer (R/M ESCC)", "status": "UNKNOWN", "last_update": "2019-02-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PYROTINIB": { "n": 2, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT06684600", "title": "Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-11-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07653451", "title": "Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] }, "RETIFANLIMAB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT05177133", "title": "Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)", "status": "RECRUITING", "last_update": "2024-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SAPITINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01579578", "title": "Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer", "status": "TERMINATED", "last_update": "2014-09-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SASANLIMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT04458259", "title": "Study of PF-07265807 in Participants With Metastatic Solid Tumors.", "status": "TERMINATED", "last_update": "2026-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "SERPLULIMAB": { "n": 10, "n_observational": 0, "n_active": 8, "n_withdrawn": 0, "trials": [ { "nct": "NCT06084897", "title": "Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy", "status": "RECRUITING", "last_update": "2024-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06354218", "title": "Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age", "status": "RECRUITING", "last_update": "2024-04-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06601309", "title": "Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC", "status": "RECRUITING", "last_update": "2025-09-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07457528", "title": "Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC", "status": "RECRUITING", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05659251", "title": "Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05942573", "title": "Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial", "status": "UNKNOWN", "last_update": "2023-07-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06388135", "title": "Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-04-29", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06496789", "title": "Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer", "status": "UNKNOWN", "last_update": "2024-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07155122", "title": "Efficacy and Safety of Serplulimab Combined With Etoposide and Cisplatin as Neoadjuvant Therapy in Limited-Stage Small-Cell Carcinoma of the Esophageal", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07403435", "title": "Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SINTILIMAB": { "n": 46, "n_observational": 1, "n_active": 23, "n_withdrawn": 1, "trials": [ { "nct": "NCT05357846", "title": "PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05495152", "title": "Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-10-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06084897", "title": "Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy", "status": "RECRUITING", "last_update": "2024-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06138028", "title": "Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer", "status": "RECRUITING", "last_update": "2024-07-24", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06190639", "title": "A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC", "status": "RECRUITING", "last_update": "2024-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06413342", "title": "Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06463834", "title": "A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06563869", "title": "Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-08-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06709417", "title": "A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)", "status": "RECRUITING", "last_update": "2024-11-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06718205", "title": "Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07751055", "title": "Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03116152", "title": "Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment", "status": "COMPLETED", "last_update": "2021-02-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03748134", "title": "Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )", "status": "COMPLETED", "last_update": "2023-10-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03940001", "title": "A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer", "status": "UNKNOWN", "last_update": "2019-09-09", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03946969", "title": "Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer", "status": "UNKNOWN", "last_update": "2022-07-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03985046", "title": "Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC", "status": "COMPLETED", "last_update": "2024-11-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04212598", "title": "The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer", "status": "COMPLETED", "last_update": "2024-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04514835", "title": "A Phase \u2161 Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC", "status": "UNKNOWN", "last_update": "2021-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04548440", "title": "Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients", "status": "COMPLETED", "last_update": "2025-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04602013", "title": "Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2020-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04625543", "title": "Neoadjuvant Immunotherapy to ESCC", "status": "WITHDRAWN", "last_update": "2022-04-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04813406", "title": "Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2021-03-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05174325", "title": "Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2021-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05199649", "title": "Correlation Between the Efficacy of Neoadjuvant Chemotherapy Combined With Immunotherapy of Operable Thoracic Esophageal Squamous Cell Carcinoma and the Metabolites of Intestinal Flora", "status": "UNKNOWN", "last_update": "2022-01-20", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05244798", "title": "Sintilimab Plus NCT or NCRT Versus NCRT for ESCC", "status": "NOT_YET_RECRUITING", "last_update": "2022-10-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05383482", "title": "Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1", "status": "COMPLETED", "last_update": "2025-11-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05625737", "title": "Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma", "status": "UNKNOWN", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05777707", "title": "Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06015035", "title": "Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer", "status": "COMPLETED", "last_update": "2023-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06078657", "title": "IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)", "status": "UNKNOWN", "last_update": "2023-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06152978", "title": "A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2023-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06161909", "title": "Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical Resection", "status": "UNKNOWN", "last_update": "2023-12-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06184841", "title": "HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2023-12-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06342167", "title": "Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06349044", "title": "A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.", "status": "UNKNOWN", "last_update": "2024-08-27", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06401447", "title": "TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06403878", "title": "Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer", "status": "UNKNOWN", "last_update": "2024-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06447636", "title": "Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06468644", "title": "Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-06-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06468670", "title": "Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-06-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06728657", "title": "Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma", "status": "SUSPENDED", "last_update": "2025-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07016737", "title": "Immunochemotherapy \u00b1 Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-06-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07067450", "title": "Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-16", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07306663", "title": "Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase \u2162 Clinical Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07385664", "title": "Neoadjuvant Chemoimmunotherapy or Chemoradiotherapy in ESCC", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07799077", "title": "Paclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SOCAZOLIMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT04460066", "title": "A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.", "status": "UNKNOWN", "last_update": "2022-05-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SPARTALIZUMAB": { "n": 19, "n_observational": 0, "n_active": 5, "n_withdrawn": 0, "trials": [ { "nct": "NCT04973306", "title": "Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC", "status": "RECRUITING", "last_update": "2022-06-30", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06008054", "title": "A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors", "status": "RECRUITING", "last_update": "2025-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06122493", "title": "Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2023-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07403136", "title": "Becotatug Vedotin \u00b1 Anti-PD-1 in Pretreated Advanced ESCC", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01351103", "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands", "status": "COMPLETED", "last_update": "2025-06-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03222440", "title": "Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC", "status": "COMPLETED", "last_update": "2019-12-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03365791", "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies", "status": "COMPLETED", "last_update": "2022-05-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03671265", "title": "Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC", "status": "UNKNOWN", "last_update": "2019-01-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03785496", "title": "Study to Evaluate Efficacy of PDR001 in Patients With Squamous Cell Carcinoma of the Esophagus", "status": "UNKNOWN", "last_update": "2021-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04000529", "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies", "status": "TERMINATED", "last_update": "2025-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04060342", "title": "GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma", "status": "TERMINATED", "last_update": "2022-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04152018", "title": "Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.", "status": "TERMINATED", "last_update": "2025-05-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04171141", "title": "Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.", "status": "TERMINATED", "last_update": "2025-01-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04641871", "title": "Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies", "status": "COMPLETED", "last_update": "2024-06-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04672434", "title": "Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies", "status": "COMPLETED", "last_update": "2024-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04802876", "title": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04821765", "title": "Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer", "status": "COMPLETED", "last_update": "2025-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06349044", "title": "A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.", "status": "UNKNOWN", "last_update": "2024-08-27", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06728657", "title": "Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma", "status": "SUSPENDED", "last_update": "2025-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SUGEMALIMAB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT07711470", "title": "Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TISLELIZUMAB": { "n": 65, "n_observational": 3, "n_active": 45, "n_withdrawn": 1, "trials": [ { "nct": "NCT04973306", "title": "Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC", "status": "RECRUITING", "last_update": "2022-06-30", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05515315", "title": "Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-02-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05919030", "title": "A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-11-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05937438", "title": "Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma", "status": "RECRUITING", "last_update": "2025-01-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05984342", "title": "Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2023-08-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06056336", "title": "Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2023-09-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06061146", "title": "Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC", "status": "RECRUITING", "last_update": "2023-12-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06084897", "title": "Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy", "status": "RECRUITING", "last_update": "2024-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06354140", "title": "PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY", "status": "RECRUITING", "last_update": "2024-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06430658", "title": "Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer", "status": "RECRUITING", "last_update": "2024-12-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06446726", "title": "Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06509568", "title": "Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma\uff08CRIS-2 Trial\uff09", "status": "RECRUITING", "last_update": "2025-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06646588", "title": "Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-10-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06690476", "title": "Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-11-15", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07039162", "title": "Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07059299", "title": "A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma", "status": "RECRUITING", "last_update": "2025-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07205731", "title": "Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma", "status": "RECRUITING", "last_update": "2026-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07317609", "title": "Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)", "status": "RECRUITING", "last_update": "2026-01-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07339488", "title": "Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07554456", "title": "A Study of BL-B01D1 in Combination With Tislelizumab \u00b15-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07554521", "title": "A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07700667", "title": "SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07811752", "title": "Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03430843", "title": "A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2024-10-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03469557", "title": "BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma", "status": "COMPLETED", "last_update": "2024-10-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03783442", "title": "A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2025-07-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03957590", "title": "A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2026-04-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04732494", "title": "Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2025-01-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04776590", "title": "Chemoradiotherapy Plus Immunotherapy Followed by Surgery for Esophageal Cancer", "status": "UNKNOWN", "last_update": "2024-04-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04802876", "title": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04819971", "title": "Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC", "status": "UNKNOWN", "last_update": "2023-04-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04821765", "title": "Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer", "status": "COMPLETED", "last_update": "2025-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05152147", "title": "A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05245760", "title": "ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer", "status": "WITHDRAWN", "last_update": "2022-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05323890", "title": "Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.", "status": "UNKNOWN", "last_update": "2023-03-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05394415", "title": "Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC", "status": "UNKNOWN", "last_update": "2022-05-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05461794", "title": "Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2025-06-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05469061", "title": "Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC", "status": "UNKNOWN", "last_update": "2022-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05520619", "title": "Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05596890", "title": "Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients", "status": "UNKNOWN", "last_update": "2022-11-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05603065", "title": "Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TINES)", "status": "UNKNOWN", "last_update": "2023-06-29", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05628610", "title": "Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05777707", "title": "Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05807542", "title": "Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC", "status": "COMPLETED", "last_update": "2024-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05880082", "title": "PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer", "status": "COMPLETED", "last_update": "2025-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06010303", "title": "A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2026-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06303583", "title": "Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma", "status": "ENROLLING_BY_INVITATION", "last_update": "2024-03-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06469060", "title": "Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06585488", "title": "A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification", "status": "TERMINATED", "last_update": "2026-07-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06692270", "title": "Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06703047", "title": "Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06914011", "title": "Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06914687", "title": "Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06965829", "title": "The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06990178", "title": "Adaptive Neoadjuvant Therapy for Esophageal Cancer", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-05-25", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07019181", "title": "Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07046221", "title": "Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07067450", "title": "Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-16", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07128693", "title": "A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07191405", "title": "Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07251062", "title": "A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-26", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07678580", "title": "Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07686926", "title": "Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07721103", "title": "Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07733180", "title": "A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TORIPALIMAB": { "n": 47, "n_observational": 5, "n_active": 23, "n_withdrawn": 0, "trials": [ { "nct": "NCT04280822", "title": "Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma", "status": "RECRUITING", "last_update": "2022-10-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06084897", "title": "Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy", "status": "RECRUITING", "last_update": "2024-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06187597", "title": "Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)", "status": "RECRUITING", "last_update": "2024-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06385730", "title": "Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)", "status": "RECRUITING", "last_update": "2024-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06657144", "title": "A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06843889", "title": "A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06912074", "title": "Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07086469", "title": "Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07177794", "title": "Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC", "status": "RECRUITING", "last_update": "2026-04-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07481058", "title": "KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07629817", "title": "Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy", "status": "RECRUITING", "last_update": "2026-07-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02915432", "title": "The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC", "status": "UNKNOWN", "last_update": "2021-12-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03474640", "title": "Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies", "status": "COMPLETED", "last_update": "2024-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03811379", "title": "Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy", "status": "UNKNOWN", "last_update": "2019-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03829969", "title": "Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2025-07-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04005170", "title": "Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer", "status": "COMPLETED", "last_update": "2022-08-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04006041", "title": "Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer", "status": "UNKNOWN", "last_update": "2019-12-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04084158", "title": "A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.", "status": "SUSPENDED", "last_update": "2021-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04177797", "title": "Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2022-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04177875", "title": "Neoadjuvant Chemoradiotherapy Combined With PD-1 Antibody in Locally Advanced Esophageal Cancer", "status": "UNKNOWN", "last_update": "2019-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04229849", "title": "Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2020-01-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04437212", "title": "Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal Cancer", "status": "UNKNOWN", "last_update": "2020-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644250", "title": "Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2020-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04804696", "title": "Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2025-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04844385", "title": "Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2024-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04880811", "title": "Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification", "status": "UNKNOWN", "last_update": "2021-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05163483", "title": "Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer", "status": "UNKNOWN", "last_update": "2023-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05424432", "title": "Short Course Neoadjuvant Chemo-radiotherapy Plus Toripalimab for Locally Advanced Resectble Squamous Cell Carcinoma of Esophagus", "status": "UNKNOWN", "last_update": "2022-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05427396", "title": "A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-12-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05777707", "title": "Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05791136", "title": "Immunotherapy After Radiotherapy in Elderly ESCC", "status": "UNKNOWN", "last_update": "2023-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05817201", "title": "Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy", "status": "UNKNOWN", "last_update": "2023-04-18", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05996484", "title": "Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma", "status": "UNKNOWN", "last_update": "2023-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06020885", "title": "Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06281886", "title": "Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2026-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06588335", "title": "BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06762158", "title": "NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06888531", "title": "Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06903871", "title": "Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06952621", "title": "Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07067450", "title": "Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-16", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07191405", "title": "Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07236320", "title": "Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC", "status": "COMPLETED", "last_update": "2025-11-19", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07246330", "title": "Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07272291", "title": "A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07332221", "title": "Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07653451", "title": "Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] }, "TRASTUZUMAB": { "n": 52, "n_observational": 5, "n_active": 19, "n_withdrawn": 2, "trials": [ { "nct": "NCT05187182", "title": "CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-04-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05188313", "title": "TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer", "status": "RECRUITING", "last_update": "2022-06-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05274048", "title": "Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients", "status": "RECRUITING", "last_update": "2025-10-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05965479", "title": "Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer", "status": "RECRUITING", "last_update": "2024-11-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06123338", "title": "A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06324357", "title": "Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06414733", "title": "HER-2 B Cell Peptide Vaccine", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07000253", "title": "Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004074", "title": "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu", "status": "COMPLETED", "last_update": "2013-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005842", "title": "Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer", "status": "COMPLETED", "last_update": "2013-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01130337", "title": "A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer", "status": "COMPLETED", "last_update": "2015-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01191697", "title": "CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer", "status": "COMPLETED", "last_update": "2025-11-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01196390", "title": "Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer", "status": "COMPLETED", "last_update": "2026-06-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01295086", "title": "Taxotere\u00ae, Eloxatin\u00ae and Xeloda\u00ae (TEX) in Combination With Herceptin\u00ae as Treatment for HER2 Positive Non-resectable Cancer", "status": "COMPLETED", "last_update": "2020-11-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01359397", "title": "Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer", "status": "UNKNOWN", "last_update": "2021-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01364493", "title": "A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer", "status": "COMPLETED", "last_update": "2017-05-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01450696", "title": "A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer", "status": "TERMINATED", "last_update": "2016-11-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01503983", "title": "Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive", "status": "COMPLETED", "last_update": "2015-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01522768", "title": "Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer", "status": "COMPLETED", "last_update": "2023-11-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01579578", "title": "Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer", "status": "TERMINATED", "last_update": "2014-09-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01705340", "title": "Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery", "status": "TERMINATED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01774851", "title": "A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach", "status": "TERMINATED", "last_update": "2017-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01928290", "title": "Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer", "status": "COMPLETED", "last_update": "2020-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02004769", "title": "Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer", "status": "COMPLETED", "last_update": "2016-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02120911", "title": "Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma", "status": "COMPLETED", "last_update": "2020-07-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02205047", "title": "Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma", "status": "COMPLETED", "last_update": "2025-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02205463", "title": "KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer", "status": "WITHDRAWN", "last_update": "2014-08-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02213289", "title": "PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression", "status": "COMPLETED", "last_update": "2021-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02318901", "title": "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer", "status": "TERMINATED", "last_update": "2019-10-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02678182", "title": "Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02954536", "title": "Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer", "status": "COMPLETED", "last_update": "2023-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03185988", "title": "Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System", "status": "UNKNOWN", "last_update": "2019-07-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03409848", "title": "Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma", "status": "COMPLETED", "last_update": "2022-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03680560", "title": "Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers", "status": "TERMINATED", "last_update": "2020-03-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03783936", "title": "Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas", "status": "COMPLETED", "last_update": "2023-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04014075", "title": "DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)", "status": "COMPLETED", "last_update": "2025-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379596", "title": "Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04430738", "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04439110", "title": "Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04464967", "title": "Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers", "status": "WITHDRAWN", "last_update": "2021-05-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04499924", "title": "Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer", "status": "COMPLETED", "last_update": "2025-01-22", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04510285", "title": "A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection", "status": "TERMINATED", "last_update": "2023-02-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04704934", "title": "Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04819971", "title": "Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC", "status": "UNKNOWN", "last_update": "2023-04-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05143970", "title": "A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05152147", "title": "A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05170256", "title": "Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients", "status": "UNKNOWN", "last_update": "2022-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05480384", "title": "Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07126561", "title": "Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TRASTUZUMAB DERUXTECAN": { "n": 8, "n_observational": 1, "n_active": 7, "n_withdrawn": 0, "trials": [ { "nct": "NCT05274048", "title": "Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients", "status": "RECRUITING", "last_update": "2025-10-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05965479", "title": "Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer", "status": "RECRUITING", "last_update": "2024-11-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06324357", "title": "Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04014075", "title": "DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)", "status": "COMPLETED", "last_update": "2025-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379596", "title": "Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04704934", "title": "Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05480384", "title": "Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07126561", "title": "Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TRASTUZUMAB EMTANSINE": { "n": 6, "n_observational": 0, "n_active": 5, "n_withdrawn": 0, "trials": [ { "nct": "NCT06324357", "title": "Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02318901", "title": "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer", "status": "TERMINATED", "last_update": "2019-10-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04439110", "title": "Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07126561", "title": "Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TUCATINIB": { "n": 3, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04430738", "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04499924", "title": "Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer", "status": "COMPLETED", "last_update": "2025-01-22", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] }, "VANDETANIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00732745", "title": "Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction", "status": "TERMINATED", "last_update": "2011-08-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01183559", "title": "A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery", "status": "COMPLETED", "last_update": "2021-01-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "ZANIDATAMAB": { "n": 4, "n_observational": 1, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT06324357", "title": "Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06695845", "title": "A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03929666", "title": "A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer", "status": "COMPLETED", "last_update": "2025-09-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05152147", "title": "A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "ZIMBERELIMAB": { "n": 5, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT04772989", "title": "A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies", "status": "COMPLETED", "last_update": "2025-08-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05329766", "title": "A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05568095", "title": "A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body", "status": "COMPLETED", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05891171", "title": "Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06250036", "title": "Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer", "status": "SUSPENDED", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ZOLBETUXIMAB": { "n": 7, "n_observational": 0, "n_active": 5, "n_withdrawn": 0, "trials": [ { "nct": "NCT06962137", "title": "Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer", "status": "RECRUITING", "last_update": "2025-12-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07000253", "title": "Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07431281", "title": "Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03504397", "title": "A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03505320", "title": "A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03528629", "title": "A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma", "status": "COMPLETED", "last_update": "2024-12-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04086758", "title": "A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma", "status": "COMPLETED", "last_update": "2024-11-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] } } } }